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ABSTRACT

Objective
The primary objective of this study was to explore a new methodological framework - Strategic
Value Driver Model (SVDM), for examining value drivers for new pharmaceutical inhaled
insulin in diabetes.

Methods
A cross-sectional, internet-based survey was used to collect a sample of 483 Type 2 diabetic
patients via national panel of diabetic patients. The sample had two subgroups - insulin-naïve
(52.9%, n=255) and insulin-user (47.1%, n=227) patients. The comparative performance of
insulin syringes/vials, insulin pen and inhaled insulin was captured on four product attributes
(i.e., safety, convenience, clinical efficacy and cost) after asking the patients to report the
importance of these attributes. The preference for inhaled insulin was used as dependent variable
for running multivariable logistic regression with summated-scale score variables for the
performance of the products as independent variables.
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Results
The respondents had an average age of 58 years. After considering product profiles and out-ofpocket monthly cost of three products, insulin pen and inhaled insulin were equally preferred
products (by 36.9% and 36.3% of patients, respectively). The preference for inhaled insulin was
significantly higher among insulin naïve patients (48.2% insulin naïve vs. 22.8% insulin users).
Performance differentiation between inhaled and pen insulin on clinical efficacy and
convenience significantly predicted the preference for inhaled insulin; whereas, performance
differentiation between inhaled and syringe/vial insulin on clinical efficacy, safety and
convenience significantly predicted the preference for inhaled insulin. A higher percentage of
insulin naïve patients placed high importance on clinical efficacy, safety and convenience than
insulin-user patients (76.9% vs. 65.8% for efficacy, 81.6% vs. 68.4% for safety, and 54.5% vs.
45.2% for convenience, respectively). The two subgroups were found to be different in terms of
predictors for the preference of inhaled insulin.

Conclusion
It will be critical for the manufacturer of new inhaled insulin to develop strategies to minimize
out-of-pocket cost for the patient, along with promoting the clinical efficacy and safety of the
new product. Furthermore, the results suggest that insulin naïve patients may be a potential
market for this new inhaled insulin. A major limitation for this study was that almost all of the
insulin-users had prior experience with Exubera (N=222, 97.4%), therefore, future research is
required to examine patients with no prior experience of Exubera.
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CHAPTER I - INTRODUCTION

New drug products are the center of attention in every pharmaceutical company because
of high development costs, low probabilities of technical success and uncertain market impact.
Almost half of the resources that the U.S. pharmaceutical industry devotes to the development of
new drug products are spent on products that have failed or been discontinued (Blau, Pekny,
Varma, & Bunch, 2004). In a generation of growing competition from generics and “me-too”
drugs, along with heightened sensitivity to healthcare spending, pharmaceutical companies have
been forced to adopt a range of strategies to respond to the changing market dynamics, like
mergers with other pharmaceutical firms, relying on biotechnology and other research firms to
provide new drug molecules under licensing, promoting new drug products with the help of new
technologies like e-detailing, and publicizing attributes of drug products to potential patients,
swaying them to seek prescriptions from their doctors (Rasmussen, 2002). These companies need
to invest in better research programs to launch new products successfully, especially products
that are in a late stage of development. Pharmaceutical companies need to promote and explain
the incremental value of the new drug product in order to gain competitive advantages in the
same drug class (Kolassa, 2009).
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Criticality of product differentiation in promoting a drug product
Pharmaceutical companies try to develop new drugs products that are superior to their
predecessors in some form or another with the hope that they will be quickly accepted. But the
fate of every new drug product is not the same, and its success depends on the development of
marketing strategies for the introduction of new drug products as much as the development of the
drugs themselves. When a new drug shows promise, a marketing strategy should be devised to
effectively differentiate the drug product from its competitors, capitalizing on its distinctive
strengths to deliver better value to its customers. This process becomes more critical when the
market under consideration is crowded and there are multiple choices. The diabetes market is a
good example of such a crowded and competitive pharmaceutical market.
Although safety and efficacy data from the clinical trials are the most important factors
influencing the acceptance of a new drug product, when the drug products are not strongly
differentiated on safety and efficacy, factors like patient preference, and, more importantly, cost,
influence the decisions of gatekeepers (e.g., physicians), and pharmacy and therapeutic (P & T)
committees (Eriksen & Keller, 1993). Therefore, in an era of high competition, it becomes
critical for pharmaceutical manufacturers to identify and target innovation-prone consumers by
effectively demonstrating the differentiation between available products and the new product.

Patient Preferences
Patient needs and perceptions are changing as the demand for better healthcare grows, so
has the desire for new and better treatments for conditions such as breast cancer, cardiovascular
disease, hepatitis and diabetes. Patients are becoming more educated and involved in their
10

disease and medication selection. They are also becoming more cost sensitive due to various
efforts by third-party payers (such as insurance companies, employers, etc.) and agencies like
AARP (American Association of Retired Persons) to promote the use of generics. In the process
of learning about a disease and its cure, a patient tends to develop preferences for certain
pharmaceutical products based on the information he/she gathers from various sources like drug
advertisements, internet, and health care providers (Hesse et al., 2005).
Many decisions need to be individualized, especially when they involve choices between
possible outcomes that may be valued in a different manner by individuals. For situations like
these, where a patient has to select from the competing alternatives on the basis of productrelated attributes, patient preference models are useful for understanding patient behavior.
Furthermore, a better understanding of patients’ assessments of the value of drug product
attributes could provide pharmaceutical manufacturers with patients’ perceptions about their
drug products in comparison to already available products in the market.
Response to new products has also been studied with the help of diffusion models which
provides some insights of adoption patterns for new technologies or products and published in
marketing literature (Phillips, Johnson, & Maddala, 2002). Although they have been used for
forecasting sales, and to direct pricing and advertising strategies (Phillips et al., 2002), little
research has been conducted to explore the process of developing preferences for new products
by individual patients.
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Value Assessment

The concept of “customer value” (CV) is widely used in marketing literature because of
its important role in predicting purchase behavior and achieving sustainable competitive
advantage (Zeithaml, 1988; Bolton & Drew, 1997; Cronin, Brady, & Hult, 2000; Dodds,
Monroe, & Grewal, 1991; Mark & Swait, 2003). Evans (2002) suggested that in order to use the
concept of CV strategically, the first task should be to identify key attributes of a product which
are highly valued by the consumers, and the next task is to identify how consumers evaluate
competing products, assuming that they make their purchase decisions with “value” as a key
driver. This approach would then lead to the identification of key drivers of customer value.

This study will examine the diabetes market and identify value drivers for a new inhaled
insulin product by measuring patients’ perceptions about the importance of different treatment
goals, and the performance of inhaled insulin in comparison to other insulin products on these
treatment goals. This analysis attempts to demonstrate the strategic value of understanding the
components that drive consumer value.

Diabetes Mellitus
Diabetes is one of the most prevalent chronic conditions in the United States, affecting
almost 7.8% of the total population (23.6 million children and adults, out of which 7.9 million
individuals are undiagnosed) (Diabetes statistics, 2007). The treatment of diabetes mellitus
requires a versatile approach of both lifestyle modification (diet, exercise, weight control,
smoking cessation) and pharmacological therapy. Usually the treatment for Type 2 diabetic
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patients starts with lifestyle intervention, which, if failed to achieve the required hemoglobin
glucose levels (HbA1c <7%), would be supplemented with a single oral agent. Further inability to
maintain required glycemic control would require the addition of another oral agent with an
alternate mechanism of action (Nathan, 2008). Beyond this point, if the patient is still facing
problems with controlling his/her HbA1c, then the physician is left with an option of either
adding a third or fourth oral insulin, or starting exogenous long-acting or short-acting insulin
(Dahlof, 1999). Following an intensive insulin therapy regimen involving multiple daily
subcutaneous injections has been shown to produce important clinical benefits in terms of
controlling hyperglycemia (Clement et al., 2004). Despite the demonstrated clinical benefits
associated with intensive insulin therapy, adherence is often observed to be poor among diabetic
patients (Korytkowski, 2002). As a result of the progressive nature of the disease, most Type 2
diabetic patients require exogenous insulin at some point in their lifetime to maintain the
glycemic blood glucose levels (UK Prospective Diabetes Study Group, 1995).
Early initiation of the insulin therapy is found to be associated with reduced risk of
developing micro and macro vascular complications in later stages of Type 2 diabetes (The
Diabetes Control and Complications Trial Research Group, 1993; UK Prospective Diabetes
Study (UKPDS) Group, 1998; Scarlett, Gray, Griffin, Olefsky, & Kolterman, 1982; Andrews et
al., 1984; Garvey, Olefsky, Griffin, Hamman, & Kolterman, 1985). There are several reasons
underlying the reluctance to start insulin therapy by patients, involving side effects of insulin
therapy, like weight gain and risk of hypoglycemic events, progression to serious stage (prelude
to death), failure of past treatment, expected pain from self injections and fear of complexity of
the insulin regimen (Korytkowski, 2002). Therefore, insulin therapy might be well tolerated by
some patients, while others may be less tolerable to the side effects or perceive it as
13

inconvenient. Elimination of these barriers to insulin therapy might have a substantial impact in
terms of achieving optimal glycemic control (Peyrot et al., 2005).
Diabetic patients often desire collaborative decision making with their health care
providers and actively seek information about their conditions and available therapeutic
alternatives. Patient preference for a medication can be simply defined as global impression of a
given treatment with respect to its pros and cons (Dahlof, 2001). Greater understanding of the
factors which influence patient preferences for different drug therapies may provide important
guidance for physicians in making rational decisions for their patient (Dahlof, 1999). The key
attributes of drug products that are often considered by physician and patient may vary by
indication but generally include some combination of: safety, efficacy, side effects, tolerability,
mode of administration, and onset of action (Dahlof, 2001; Mark & Swait, 2003).

Research Objectives
A new inhaled insulin system is currently under development. The arrival of a new
insulin delivery system into the market will provide diabetic patients with another alternative for
administering insulin, which is predominantly delivered by syringes and pens. A major
advantage offered by inhaled insulin over traditional insulin products might be its added
convenience. However, that needs to be empirically tested.
As lack of public appeal for Exubera (inhaled insulin by Pfizer launched in 2006) was
considered to be the primary reason behind its removal from the market in 2007 (Pinto, HolidayGoodman, Black, & Lesch, 2009), it will be critical for the manufacturer of new inhaled insulin
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to measure patients’ perceptions about the product and identify ways to differentiate the new
insulin product from currently available short-acting insulin syringe/vials and pens. This leads us
to the following research objectives:
•

To examine patients’ perceptions about current injectable insulin in comparison to inhaled
insulin and to use these measures to predict their preferences for the new inhaled insulin
product. This will help calculate the derived importance of product performance.

•

To explore differences between insulin users and non-insulin taking (naïve) diabetic patients
in terms of value drivers for the new inhaled insulin product.
The specific aim of this study was to explore and develop strategic insights related to

value drivers for inhaled insulin using the Strategic Value Driver Model (SVDM). Specifically,
this study examined the role of product attributes in the decision to purchase an insulin delivery
system by identifying the most important attribute(s) driving the value of the new insulin
product. The criticality of the product attributes and relative performance of three insulin
delivery systems were evaluated based on economic and marketing theories.

Significance
This study helped identify the most important product attributes that influence patients’
preferences for the new inhaled insulin. Furthermore, the results were used in developing the
value drivers for the new inhaled insulin using SVDM and helped demonstrate the value of the
SVDM method for evaluating product performance and developing marketing strategies. The
results from this study will have the potential to assist pharmaceutical companies in developing
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marketing and promotional plans for new products for diabetes. By identifying patients who
would value a new product more, pharmaceutical companies can develop more effective
promotional plans. This method can also be used for determining the value of other
pharmaceutical products and help in pricing those products. If a new product’s performance is
perceived to be better than its competitor is, it can better support a premium price compared to
other products in the same market.
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CHAPTER II – LITERATURE REVIEW

“Customer value is a customer’s perceived preference for and evaluation of those product attributes,
attribute performances, and consequences arising from use that facilitate (or block) achieving the
(Woodruff, 1997)

customer’s goals and purposes in use situation”

The Concept of Value
A vague description of the concept of value was first based on philosophical views, but
later the introduction of terms like “use value” and “exchange value” provided a better
understanding of the term “value” (Woodall, 2003). In the 18th century, the utilitarian approach
provided some explanation of how value-related choices could be made but was not of much use
in explaining the decision-making process itself (Woodall, 2003). According to economists,
choices made by customers are assumed to be based on utility maximization (Machina, 1987).
According to this approach, consumers make decisions by selecting a product or service based
on their assumption of gaining maximum utilities from that product or service.
Zeithaml (1988) suggested that perceived value could be regarded as an overall
assessment of a product’s utility based on the perception of what is received and what is given in
the whole process. Zeithaml also argued that some consumers perceive value when price is low,
whereas others perceive greater value when there is a balance between quality and price. Cost
plays an important role in patients’ decision making regarding adopting a new product; however,
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cost is not equal to value since some consumers relate price to quality and may perceive more
costly products to be higher in value than other available options.
Another concept of value was explored by Rokeach (1973), according to which every
individual possesses a set of personal values that act as motivational forces in terms of guiding
the individual through the decision making process. Since it is well known that every individual
evaluates the utility gained in a different way, it could mean that every individual possesses a
different set of values that motivates the decision-making process. Stern (1979) named those sets
“internal drivers”, which makes these individuals express their choices in an entirely unique
ways. Frondizi (1971) suggested that value differentiating characteristics may exist not only
within individuals, but also within the objects. Various other authors suggested a similar
explanation for value, like Heskett, Loveman, Sasser, & Schlesinger (1994), who claimed that
“value drives customer satisfaction” and Hallowell (1996), who suggested that “satisfaction is
the customer’s perception of the value received in a transaction or relationship”.
The literature on the concept of value is as broad and extensive in the fields of marketing,
as it is in the field of economics and philosophy. In the marketing literature, Gale (1994), was the
first one to quantify the concept of perceived value by mapping the rating scores of comparative
products on the customers’ perceptions about product quality and price. He calculated customer
value (market-perceived quality rating) using the formula:
Customer Value = (Relative overall quality score * Quality weight) + (Relative price
competitiveness score * Price weight).
Here, the relative overall quality score is the ratio of quality scores of comparative
products for an attribute, and quality weight is the weight assigned to that attribute by the
18

customer. He suggested that the overall customer value should be more than 13⅓ percent in
order to position the product in a superior value position (In other words, the overall marketperceived ratio, MPR, should be greater than 1.133).
Buyers’ perceptions of value represent tradeoffs between quality and benefits they
perceive in the product, relative to the sacrifices they perceived in terms of price they paid
(Monroe, 1990). Woodruff defined customer value as a “customer’s perceived preference for and
evaluation of those products attributes, attribute performances, and consequences arising from
use that facilitate (or block) achieving the customer’s goals and purposes in use situations”
(Woodruff, 1997).
Although the strength of a relationship between a customer and a product could be
determined both by product attributes and the personal values of the customer (Rokeach values)
(Rokeach, 1973), for the purpose of this study, we will restrict ourselves to the evaluation of
product attributes. Frondizi (1971) called relevant product attributes “intrinsic values” which are
different from the “extrinsic values” (which are associated with the use or exchange of a
product). He also suggested that product attributes that are valued by customers becomes
intrinsic values of those products.
Based on the explanations provided by various authors, Woodall explained five primary
forms of value for the customer (Figure 1, page 14) (Woodall, 2003). He explained “Net VC” as
a utilitarian perspective where customers try to determine the ratio of benefits and sacrifices,
where more benefits would mean good VC. “Derived VC” is perceived by a customer only after
experiencing the product or service (derived in nature).
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Figure I:: Forms of “Derived VC” (Woodall, 2003)

“Sale VC” is meant to be associated with reduction of sacrifices (in terms of reduced cost or
effort) rather than increasing
ng benefits. Woodall explained “Rational VC” as the difference from
objective price, which the customer ev
evaluates as a fair price for a product (e.g., plus $30 for good
value and minus $20 for bad value).
The form of value which is of interest for strategic marketing pla
plans
ns for pharmaceutical
drugs is “Market VC,” which is proposed to be based on the preferences of the product attributes.
attribu
Woodall suggested that this form of VC is ass
associated
ociated with Frondizi’s (1971) “intrinsic value”
concept. According to Woodall, Marketing VC is composed of two types of components –
proposed (supplier) andd perceived (customer)
(customer). In general, every customer has his/her own value
system (Rokeach, 1973),, which is difficult for the supplier to predict.. Therefore, the supplier
comes up with a product or a service (proposed component) which would be valued by
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customers in a generalized way. Therefore, when a customer is provided with a new product, the
proposed and perceived component of value interacts and gives real “Marketing VC.”
Figure 2 (page 16) represents the conceptual model of deter
determination
mination of value of a
pharmaceutical product from a decision maker’s perspective, developed by Kolassa (2009). In
this model, the value of a new pharmaceutical product depends on the positive construct of
benefit and negative construct of risks. Benefit is derived from perceived unmet need, criticality
and a comparison to alternatives. Risk can be defined by the amount of effort involved in
adopting a new product (like learning a new dosing schedule) and also by a level of uncertainty
associated with the performance of a new product. These constructs are usually assessed in
comparison to already available options in the market.

Figure II:: The Determination of Value (Kolassa, 2009)
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Overview of Methods Used to Determine Value of Pharmaceutical Products
Many decisions need to be individualized, especially when they involve choices between
possible outcomes that may be viewed differently by patients. For situations like these, where a
decision maker has to select from competing alternatives on the basis of product-related
attributes, patient preference models are useful for understanding patient behavior and for
subsequent development of new drug products (Bingham, Johnson, & Miller, 2001). Two broad
approaches have usually been discussed in the literature:
1. “Attitude” surveys usually involve ranking and/or rating of different products (Weiss &
McHorney, 2007). In social psychology, “Attitude” is defined as “a psychological tendency
that is expressed by evaluating a particular entity with some degree of favor or disfavor”
(Eagly & Chaiken, 1996).
2. “Preference” surveys supported by economic theory measure utility associated with the
products.
Preference surveys are often used for measuring an individual’s value for health care
goods and services. These surveys are utilized to derive utility values by methods like rating
scales, time trade-off, and standard gamble. They have also been used in the forms of contingent
valuation methods (CVM), conjoint analyses (Johansson, Torling, & Karlsson, 2004) and
discrete choice experiments (de Bekker-Grob et al., 2008). CVM is often used for willingness to
pay studies and cost benefit analyses. Whereas conjoint analysis is commonly used to determine
how people value different components of a service or a product. One drawback to it is that it
provides preferences for hypothetical combinations of product attributes and product selections
that do not necessarily reflect the real nature of product selection. Although conjoint analysis can

22

provide relative measures for the importance of product attributes, this method provides limited
information about the sources of perceived value of the product attributes and thus is unable to
provide strategic insights of product preferences, which is a very important piece of information
for product promotion teams (Park & Srinivasan, 1994).

Strategic Value Driver Model (SVDM)
Drawing on the literature on value assessment, it can be proposed that the value of an
individual product attribute is a function of the importance of an attribute, the product’s relative
performance on that attribute compared to its competitor, and the level of unmet need for that
attribute in the current market. Marketing strategies can be used to increase a product’s overall
value on an attribute by increasing the importance of that attribute, increasing positive
differentiation of the product on that attribute, or increasing awareness of the perceived unmet
need.
For exploring the value of pharmaceutical product attributes in order to develop
marketing strategies based on the exploration, it is important that a method be used that provides
information about each component of value. For this project, the conceptual framework used is
referred to as the Strategic Value Driver Model (SVDM) (Figure 3, page 18). This model is
based on the theory of multi-attribute utility which states that utility is gained from the attribute
or properties of a product or service rather than the product or service per se (Lancaster, 1966).
Since value is linked to the utility associated with an attribute, the model measures perceptions
related to treatment goals that express different utilities that would be associated with product
attributes.
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Figure III: Strategic Value Driver Model (SVDM)

SVDM suggests that the examination and development of value drivers for a new
pharmaceutical drug starts with assessing the importance of product attributes, by asking patients
to rate the importance (importance ratings) of each attribute. This is followed by assessing how
well the new pharmaceutical drug and other drug alternatives or currently-available drugs
perform on each product attribute.
This approach allows one to explore both the stated and derived importance of each
product attribute individually, which helps in developing strategic insights of how the value for a
product is created. Stated importance is measured by having patients rate the importance of each
product attribute (Chu, 2002). Stated importance may not actually drive the product use since it
does not account for the relative product performance on the attribute (or the level of unmet
need). The overall value of a product on an attribute is closely associated with its derived
importance. Derived importance is measured by the statistical correlation between differences in
product attribute ratings (predictors) for the products and the intention to use that product
24

(criterion) (Hanson, 1992). Logistic regression coefficients or the odds ratios are generally used
to develop the derived importance for product attributes (Chu, 2002). Marketing strategies are
developed through derived importance by examining the differentiation on an attribute and its
pay off in terms of preference for the new product. If this association is not strong, it could be
due to a lack of importance being placed on that attribute or the product’s poorly perceived
performance (or performance rating) on that attribute. The SVDM approach provides marketing
personnel with all the information needed to identify the most important drivers of potential use
and to identify the components that marketing strategy can try to leverage to increase product
use.
As stated in Chapter 1, this study examined the value drivers for new inhaled insulin for
Type 2 diabetic patients. Therefore, the appropriate product attributes that were examined are
categorized in four general groups:
Safety: This category includes the measures of risks and/or side effects and weight gain
associated with the use of insulin products (Cefalu, 2002; Peyrot et al., 2005). New inhaled
insulin with reduced amount of risks or side effects might be perceived as more valuable than
currently available treatment options – injectable insulin (syringes and pens).
Convenience: The convenience of taking insulin could be defined in terms of social
acceptability, ease of use and activity interference (Summers, Szeinbach, & Lenox, 2004).
Taking insulin injections in front of others might be inconvenient and socially undesirable for
some patients, whereas for others it might not be a problem at all (Testa & Simonson 2007).
Previous research suggests that taking insulin injections is more inconvenient than inhaling
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insulin (Testa & Simonson, 2007; Pinto et al., 2009; Rosenstock, Cappelleri, Bolinder, & Gerber,
2004).
Clinical efficacy: This is defined in terms of the clinical goals, time of onset of action and
duration of action of the insulin. Usually one would expect the patients to be only concerned
with cost and convenience of a medication, but studies have shown that some patients inquire
about the clinical efficacy of a drug and consider it during evaluation (Weiss & McHorney,
2007; Ferrari et al., 2005).
Cost: Previous research suggests that patients’ out of pocket costs for their drugs influence their
prescription fill behavior and product preferences (Dranitsaris, Elia-Pacitti, & Cottrell, 2004;
Mahadevia et al., 2006). A study by Pinto et al., (2009) showed that the patients who were
unsatisfied with their current diabetes therapy were ready to pay more for new inhaled insulin, if
available.
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CHAPTER III – RESEARCH METHODOLOGY

Operationalization of Variables
Independent variables
The four categories of product attributes: safety, convenience, clinical efficacy and cost,
were examined using different descriptions or measures (Table I, page 25). These different
measures were adapted from previous research that examined diabetic patients’ satisfaction with
insulin treatment and perceptions about diabetes medication (Testa & Simonson 2007; Monahan,
Lane, Hayes, McHorney, & Marrero, 2009; Anderson et al., 2004). The importance (or
criticality) of each of these product attributes were examined by asking them to rate the
importance of each measure on a Likert-type 7 point scale, (where 1 – “Not important at all” and
7 – “Very important”). Following this rating exercise, patients were presented with product
profiles of insulin syringes/vials, insulin pens and new inhaled insulin. Patients were then
required to rate how well the new inhaled insulin and currently available injectable insulin
(syringes and pens) performed on the same product attribute measures. A Likert-type 7 point
scale where 1 would mean “the product performance is worst on this item” and 7 would mean
“the product performance was best on this item,” was used to assess patients’ perceived
performance ratings for the three products on the treatment goal measures. These ratings were
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used to determine if inhaled insulin is “Worse than,” “Not differentiated” or “Better than” the
injectable insulin.

Table I: Product attributes and their respective descriptors/measures
S. No.
1
2
3
4
5

6

7
8
9
10
11
12
13
14
15
16

Treatment goals
Control blood sugar (glucose) levels to goal levels
Keeping your blood sugar levels stable (avoiding
high and low blood sugar levels)
Fasting (morning before breakfast) blood sugar
(glucose) levels to goal levels
Post-prandial (after meal) glucose levels to goal
levels
Avoiding symptoms of low blood sugar or
hypoglycemia (such as sweating, trembling,
dizziness, blurred vision and fast heart beat)
Reducing the possible side effects of insulin
medication, like allergic reactions and reactions at
the injection site which may cause redness,
swelling and itching
Minimizing weight gain from insulin therapy
Flexibility in time required between insulin dose
and eating
Minimizing the frequency of monitoring blood
sugar (glucose) with finger-stick test
Convenient for me to carry with me during the day
Making it easy to take insulin in a public place
(where people might see you)
Reducing the pain or discomfort of taking insulin
Making it easy to accurately measure the correct
dose of insulin
Selecting the best product I can afford
Selecting the products with the lowest out-ofpocket cost
Selecting a product that I can afford
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Construct
Efficacy
Efficacy
Efficacy
Efficacy
Safety

Safety

Safety
Convenience
Convenience
Convenience
Convenience
Convenience
Convenience
Cost
Cost
Cost

Dependent variables
For the dependent variable, respondents were asked to select a preferred product among
the syringe/vial, pen and inhaled insulin. Then they were asked to state their likelihood to use
inhaled insulin if their doctor recommended it. The likelihood to use was examined using an
ordinal 5-point scale where 5 meant “definitely would,” 4 - “probably would,” 3 - “not sure,” 2 “probably would not,” and 1 - “definitely would not.” A re-assessment based on physicians’
recommendations was necessary as patients may not make a decision to switch to new inhaled
insulin without their doctors’ recommendations or prescriptions (Freemantle et al., 2005).

Product profile development
The product profiles were created to reduce the knowledge gap in insulin users and
insulin naïve patients and also to educate them about the new inhaled insulin product. The
readability of the profiles was close to 9th grade level and considered appropriate for internet
users (Walsh & Volsko, 2008). Information under each product profile was presented in a similar
format in terms of efficacy, dosing, side effects, storage, and out of pocket monthly cost of the
products, so that patients can easily compare all three products. The clinical information for the
product profiles was gathered from package inserts of relevant products and various patient
friendly websites. The product profile can be viewed in Appendix B.

Survey Instrument Development
Along with operationalized variables, the survey also collected disease-specific
information which included length of diabetes (years), current therapy type (oral and/or insulin),
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device used to administer insulin (needle/syringe or pen), number of oral anti-diabetic tablets and
frequency of administering insulin per day. An item was included for insulin users to capture
their satisfaction and the level of pain experienced with their current insulin products.
Demographic information (including weight and height for BMI calculation) was collected
towards the end of the survey. The survey instrument can be viewed in Appendix A.

Data collection and Study sample
A cross-sectional, internet-based, self-administered survey was used to collect the data.
The survey was programmed using Qualtrics, a web-based tool used for designing and
distribution of the survey over the Internet. Research participants were recruited from a national
panel of diabetic patients provided by a market research consulting firm. A web-based survey
was conducted as it allows rapid data collection from a widely dispersed and large sample
(Evans & Mathur, 2005).

Study Sample
Type 2 diabetic patients were included in this study since patients with Type 1 diabetes
constitute a small percentage of all diabetics, and a collection of a significant number of
respondents with Type 1 diabetes would have increased the recruitment times and costs of data
collection. Since it was of interest to see how patients naïve to insulin therapy would behave in
comparison to those who are already taking insulin, this study used quota sampling to ensure a
roughly equal split between:
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1. Type 2 diabetic patients who were taking injectable insulin, either alone or with oral antidiabetes drug(s), via syringes or pens, and
2. Type 2 diabetic patients, naïve to insulin. This group of patients was on at least 2 oral antidiabetic drugs.
The reason for including Type 2 diabetic patients naïve to insulin therapy was that they
might face a situation in the near future (which was made sure by controlling the severity of the
disease, by selecting the patients who were on at least 2 oral anti-diabetic drugs) where, their
HbA1c will not be controlled by oral medications, and their physicians may recommend starting
insulin therapy. And some patients may also be in stages where their doctors may have
considered starting them on insulin therapy.
As the patients are at different stages of diabetes, (insulin naïve and insulin taking), their
purposes for evaluating new inhaled insulin will also be different. Insulin-taking patients might
consider the new product as replacements for their current products whereas insulin naïve
patients may consider it for adopting a new therapy all together.
Based on previous studies that examined diabetic patients’ preferences for diabetes
products (e.g., Pinto et al., 2009) and considering the length of the survey, a total sample size of
483 was collected for this study.

Pretest
The survey was pre-tested in a two-step process. In the first step, the survey was given to
Four trained diabetes educators (in the Department of Pharmacy Practice at the University of
31

Mississippi) to examine the level of understanding of the survey and clarity of the product
profiles. Based on their input and after making appropriate changes, the survey was then tested
using a convenience sample of staff members at the University of Mississippi with diabetes.
Ultimately, the face and content validity of the survey was evaluated by Pharmacy
Administration faculty and graduate students at the University of Mississippi. During these pretests, the approximate time taken to complete the survey and reading difficulty level were also
examined. Appropriate revisions to the questionnaire were conducted after the pretests.

Analysis Plan
Data was analyzed using IBM SPSS®. Demographic characteristics and descriptive
statistics were generated to describe the study sample. Reliability of the measures used to assess
product attribute goals were assessed using Cronbach’s alpha and item-to-total correlation
analysis. All statistical tests were 2-tailed, and the tests of significance were conducted at 0.05
level of significance. The specific analysis planned for meeting each of the research objectives
are described in the following sections.

Objective 1: To examine patients’ perceptions about current injectable insulin in comparison to
inhaled insulin, and to use these measures to predict their preference for the new inhaled insulin
product.
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The derived importance of differences in product perceptions was examined using both
univariate and multivariable analysis. Two difference-scores for each product attribute measure
were computed by subtracting (1) the rating for injectable insulin - syringe/vials from the rating
for inhaled insulin and (2) rating of injectable insulin - pen devices from the rating for inhaled
insulin on that product attribute measure. This gave two difference-score variables for each of
the product attribute measures: clinical efficacy, convenience, safety and cost.
The difference score variables were then used to develop a summated-scale score for
each product attribute (e.g., using the 3 difference-score efficacy measures we developed an
overall efficacy summated-scale score). As a result of this, four overall summated-scale score
variables, one for each product attribute, were created for further analyses. The summated-scale
score variables were then converted into a categorical variable using the following criteria. If the
summated-scale value was greater than 0, then the scale was defined as “Inhaled insulin is better
than injectable insulin.” If the value was less than 0, then it was defined as “Inhaled insulin is
worse than injectable insulin.” If the value was equal to 0, then it was defined as “Inhaled insulin
is not differentiated injectable insulin.”
Univariate tests - Cross-tabs and chi-square statistics were used to examine the relationship
between the calculated categorical summated-scale score variables and the most preferred
product, which was also categorized into two levels –“Inhaled insulin” (if inhaled insulin is
selected out of all the options) and “Others” (if insulin needle/syringe, insulin pen, or no
preference, will take whatever the doctor prescribes is selected).
Multivariate tests - Logistic regression was used to identify the strongest overall predictors of
preference for inhaled insulin. The categorical measure of preference for inhaled insulin was
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used as the dependent variable. The independent variables were the categorical summated-scale
score variables for the performance on four product attributes.

Objective 2: To explore differences in insulin users and insulin naïve (not taking insulin) diabetic
patients in terms of value drivers for a new inhaled insulin product.

The same univariate and multivariate analyses conducted for objective 1 was re-run to
answer this question. However, these analyses were conducted separately for insulin naïve and
insulin-taking patients.
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CHAPTER IV – RESULTS

Data was collected with the help of a market research vendor, e-Rewards. The sampling
frame for this study included self-reported Type 2 diabetic patients who were members of a
diabetic panel maintained by e-Rewards (which included 45,408 Type 2 diabetic patients). The
survey invitation web link that was provided to e-Rewards, was used to invite a sample of
diabetic patients. 1,493 patients accepted the invitation and responded to the survey, out of which
516 were eligible and participated in the study. After excluding the patients (N=33) who did not
differentiate between any of the insulin products and marked “Do not have sufficient
information” on all product performance items, a sample of 483 patients was used for the
analysis. It was assumed that if the patients had not read the entire product profiles, they would
not be able to differentiate in between the products.
Data was collected over a span of six days, November, 16th through November, 21st 2010.
Table II depicts the number of patients that responded each day. For the first two days, fewer
people were invited as part of a soft launch in order to ensure proper working of the logic of
branching and quotas. The raw data was downloaded from the Qualtrics software in IBM SPSS
format. The final dataset was visually inspected for out-of-range and missing values.
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Table II: Schedule of data collection
Date
Tuesday, 16 November 2010
Wednesday, 17th November 2010
Thursday, 18th November 2010
Friday, 19th November 2010
Saturday, 20th November 2010
Sunday, 21th November 2010
th

Completed responses
7
31
96
255
88
39

Cumulative responses
7
38
134
389
477
516

Sample description
A total of 482 responses were used for the final analysis, out of which 47.1% (n=227)
were using insulin (either with or without diet, exercise and oral anti-diabetic pills) to control
diabetes, and the remaining 52.9% (n=255) were insulin naïve (either with or without diet,
exercise). The two groups were similar across all demographic variables except for the annual
household income. A higher percentage of insulin naïve patients had income over $75,000 in
comparison to the insulin-using patients (41.56% vs. 29.51%, respectively; χ2=12.586, df=5, p =
0.028). Respondents had an average age of 58 years with a slight over-representation of males
(54.2% - males, 45.8% - females). The sample was fairly educated with 54.3% of respondents
having at least a Bachelor’s degree (four-year degree). Of the respondents, 51% mentioned that
they never smoked, whereas 39.7% reported themselves as ex-smokers. The respondents were
asked to report their weights and heights, which were later used to calculate their BMI. The
calculated BMI was then divided into 3 categories – normal weight (BMI <25), overweight (BMI
= 25-29.9), and obese (BMI >=30) (Heisler, Kieffer, Piette, Vijan, & Spencer, 2005). The
majority (70.9%) of the respondents were found to be in the obese category. A summary of
demographic information is presented in Table III.
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Table III: Baseline characteristics of the sample

Sample
Male
Female
Up to 45 years
45-65
65 and above
Caucasian/White
Other
Up to $ 24,999
$ 25,000-49,999
$ 50,000-74,999
$ 75,000-99,999
$ 100,000 and above
Do not wish to answer
High school diploma
Some college
Associate’s degree
Bachelor’s degree
Master’s degree
Doctoral degree
Non-smoker
Regular smoker
Occasional smoker
Ex-smoker
Normal weight (<25)
Overweight (25-29.9)
Obese (≥30)

Insulin naïve
Insulin taking
N
%
N
%
255
52.9%
227
47.1%
Gender
130
54.2%
110
51.6%
110
45.8%
103
48.4%
Age
24
10%
25
11.8%
159
66.3%
137
64.6%
57
23.8%
50
23.6%
Ethnicity
211
87.9%
187
87.8%
29
12.1%
26
12.2%
Annual household income*
22
9.2%
16
7.5%
41
17.1%
39
18.3%
45
18.8%
60
28.2%
41
17.1%
33
15.5%
65
27.1%
34
16.0%
26
10.8%
31
14.6%
Highest level of education
31
12.9%
23
10.8%
51
21.3%
51
26.3%
28
11.7%
20
9.4%
68
28.3%
69
32.4%
47
19.6%
32
15.0%
15
6.3%
13
6.1%
Smoking status
124
51.7%
107
50.2%
13
5.4%
15
7.0%
8
3.3%
6
2.8%
95
39.6%
85
39.9%
BMI
13
7.9%
12
8.1%
36
22.0%
30
20.1%
115
70.1%
107
71.8%

Total
N
482

%

240
213

53%
47%

49
296
107

10.8%
65.5%
23.7%

398
55

87.9%
12.1%

38
80
105
74
99
57

8.4%
17.7%
23.2%
16.3%
21.9%
12.6%

54
107
48
137
79
28

11.9%
23.6%
10.6%
30.2%
17.4%
6.2%

231
28
14
180

51.0%
6.2%
3.1%
39.7%

25
66
222

8.0%
21.1%
70.9%

*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the
annual household incomes of two groups at p < 0.05 significance level.
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Nearly half (45.2%) of the respondents reported their diabetes to be under control with
HbA1c values under 7%. 91.5% had some kind of insurance that paid for their diabetic
medications, whereas fewer (69.5%) had insurance coverage for insulin devices. The average
duration of diabetes for the entire sample was 11.24 years. Table IV represents the summary of
disease specific characteristics. Insulin naïve patients were different from insulin users in terms
of reported HbA1c test values, with insulin naïve patients having good glycemic controls
(χ2=20.632, df=4, p < 0.001). In terms of insurance for insulin devices, as expected, a higher
percentage of insulin users had it in comparison to insulin naïve patients (χ2=77.863, df=2, p <.
001). Also, the number of years with diabetes was higher in insulin users (χ2=34.348, df=4, p <
0. 001).
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Table IV: Disease specific characteristics

Sample
<7%
7-7.9%
8-8.9%
≥9%
Don’t know
<5%
<6%
<7%
<9%
Correct
Incorrect
Yes
No
Yes
No
Do not know
Up to 2 years
3-5
6-10
11-15
16 and above

Insulin naïve
Insulin taking
N
%
N
%
255
52.9%
227
47.1%
HbA1c test value*
129
50.6%
89
39.2%
71
27.8%
59
26.0%
21
8.2%
35
15.4%
9
3.5%
27
7.4%
25
9.8%
17
11.9%
Target HbA1c value*
19
7.5%
22
9.6%
107
42.0%
76
33.3%
123
48.2%
114
50.0%
6
2.4%
16
7.0%
HbA1c assessment
84
32.9%
83
36.4%
171
67.1%
145
63.6%
Insurance of diabetes medication
234
91.8%
208
91.2%
21
8.2%
20
8.8%
Insurance of insulin devices*
137
53.7%
199
87.3%
53
20.8%
27
11.8%
65
25.5%
2
0.9%
Number of years with diabetes*
15
5.9%
8
3.5%
72
28.2%
32
14.0%
82
32.2%
69
30.3%
58
22.7%
51
22.4%
28
11.0%
68
29.8%

Total
N
482

%

218
130
56
36
42

45.2%
27.0%
11.6%
7.4%
8.7%

41
183
237
22

8.5%
37.9%
49.1%
4.6%

167
316

34.6%
65.4%

442
41

91.5%
8.5%

336
80
67

69.6%
16.6%
13.9%

23
104
151
109
95

4.8%
21.5%
31.4%
22.6%
19.9%

*Comparisons based upon the Pearson chi-square statistics for column portions showed significant differences in the
HbA1c test values, target HbA1c, insurance for medical devices and number of years with diabetes in two groups at
p < 0.05 significance level.
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Clinical knowledge of diabetes
Before looking into the importance that diabetic patients placed on various treatment
goals, their understandings of some clinical aspects were captured using a 3-item scale (Table
V). The majority of Type 2 diabetic patients had a good knowledge of HbA1c tests. A higher
percentage of patients were aware of fasting blood glucose levels (80.5% marked high
knowledge on a 7-point scale) in comparison to prandial blood glucose levels (69%). In general,
the patients had a good understanding of the clinical aspects of diabetes.

Table V: Understanding of clinical aspects of diabetes
Items

Mean ± SD*

Percentage of patients in top
2 boxes (i.e., rated 6 & 7)**
442 (91.5%)

HbA1c test and its meaning for 6.43 ± 0.92
a person with diabetes
Achieving the required fasting 6.07 ± 1.07
blood glucose levels
Achieving the required post5.86 ± 1.16
prandial blood glucose levels

389 (80.5%)
334 (69.1%)

*Mean ± SD (range) importance ratings out of 7. Where 1= Not at all important, and 7 = Extremely important.
**represents the patients who marked importance of an item to be very high (i.e., marked 6 or 7 on a 7 point scale).

Furthermore, respondents’ clinical knowledge of HbA1c was checked with the help of
their self-evaluations of their levels of diabetes control. It was assessed by asking the results of
their most recent HbA1c test values and the state of their diabetes based on those values (Heisler
et al., 2005). Based on this information, a dichotomous variable was created (“Yes” – correct
assessment, “No” – wrong assessment), which served as a proxy for the respondents’ selfevaluations and understanding of clinical aspects of diabetes. 34.6% (n = 167) of the diabetic
patients correctly assessed the states of their diabetes based on HbA1c test values (Table IV).
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Medication use pattern
As per the eligibility criteria for this study, patients were required to be on insulin therapy
or a minimum number of 2 OADs. Every patient was found to be on some form of a combination
of diet and exercise, OADs, insulin injections and/or non insulin injections like Byetta and
Victoza. 35.4% of the diabetic patients were on a combination of diet and exercise, and OADs
whereas 18.6% were taking OADs and insulin along with diet and exercise. Only 7.6% were
taking insulin along with diet and exercise. Overall, 400 diabetic patients (82.9%) were taking at
least 2 oral anti-diabetic medications (either alone or in combination with diet/exercise and/or
insulin therapy), whereas, about 68.6% (n = 331) of the diabetic patients mentioned that they
were on diet and exercise (either along with OADs and/or insulin injections and/or non-insulin
injections like Byetta and Victoza) (Table VI).
As far as the distribution of the type of OAD was concerned, a somewhat similar pattern
was observed between insulin users and insulin naïve groups. Out of all the drug classes, the uses
of Biguanides (67.2%), Sulfonylureas (49%), and Thiazolidinediones (27.2%) were found to be
most prevalent. The information on the use of pen, syringe/injections for administering insulin
was also collected and is displayed in Table VI. In this sample, we found more pen users in
comparison to syringe/vial users (23.2% vs. 18.4%, exclusive of “both pen and syringe
category”).
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Table VI: Current treatment regimen

Sample
Diet and exercise
Oral anti-diabetics
Insulin injections
Insulin pump
Non-insulin injections
Sulfonylureas
Meglitinides
Biguanides
Thiazolidinediones
Alpa-glucosidase
inhibitors
DPP-4 inhibitors
Insulin pens only
Syringes only
Both pen and syringe

Insulin naïve
Insulin taking
N
%
N
%
255
52.9%
227
47.1%
188
73.7%
143
63%
255
100%
145
63.9%
227
100%
3
1.3%
24
9.4%
19
8.4%
Oral anti-diabetics
175
68.6%
61
26.9%
16
6.3%
8
3.5%
226
88.6%
98
43.2%
105
41.2%
26
11.5%
2
0.8%
3
1.3%

N
482
331
400
227
3
43

%
100%
68.7%
83.0%
47.1%
0.6%
8.9%

236
24
324
131
5

49%
5%
67.2%
27.2%
1.0%

53

8.4%

72

14.9%

49.3%
39.2%
11.5%

112
89
26

23.2%
18.4%
5.4%

-

20.8%
19
Insulin injection device
112
89
26

Total

Reliability
The reliability of the product attributes (i.e., clinical efficacy, safety, convenience, and
cost) and understanding of clinical aspects of diabetes was assessed by calculating Cronbach’s
alpha for each construct (Table VII). All the constructs had a Cronbach’s alpha well over 0.7 and
had item-to-total correlations (correlations of individual items to the summated score of the
scale) exceeding 0.5, indicating high internal consistency among the constructs. The mean interitem correlation (correlations of individual items to other items on the scale) also exceeded 0.3
for all the five constructs, further assuring the reliability of the scales (Hair et al., 2006;
Cronbach, 1951).
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Table VII: Summary of scale properties
Scale
Clinical Efficacy
Safety
Convenience
Cost
Understanding of clinical
aspects of diabetes

Number of items
4
3
6
3

Cronbach’s alpha
0.880
0.787
0.868
0.918

3

0.873

Satisfaction with current insulin product
Diabetic patients were asked to report the level of satisfaction with the insulin product
they were currently using, on a 5-point Likert type scale (“Very dissatisfied,” “Somewhat
satisfied,” “Not sure,” “Somewhat satisfied,” “Very satisfied”). Due to lower cell numbers,
satisfaction was converted into a dichotomous variable – “Yes” (for “Somewhat satisfied” and
“Very satisfied”), “No” (for “Very dissatisfied,” “Somewhat dissatisfied,” and “Not sure”).
Overall, 77.6% (N=120, total number of insulin pen users) of patients were satisfied with pens,
and 55.8% (N=106, total number of insulin syringe/vial users) of patients were satisfied with
syringes. Cross-tab results for satisfaction and HbA1c levels can be seen in Table VIII. The
relationship between HbA1c values and satisfaction with current insulin product used was
examined with the help of Pearson Chi-square tests. Although, with the increase in HbA1c
values (uncontrolled HbA1c levels), a fewer percentage of patients were satisfied with
syringe/vial insulin, but the effect was not statistically significant.
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Table VIII: Association of HbA1c values with preference for inhaled insulin and
satisfaction with current insulin product use
HbA1c
value
<7%
7-7.9%
>8%

Satisfaction with pen
No
7(13.5%)
12(32.4%)
9(25.0%)

Yes
45(86.5%)
25(67.6%)
27(75.0%)

Satisfaction with
syringe/vial
No
Yes
14(28.6%) 35(71.4%)
10(40.0%) 15(60.0%)
15(46.9%) 17(53.1%)

Preference for inhaled
insulin
No
Yes
72(80.0%) 18(20.0%)
41(69.5%) 18(30.5%)
48(77.4%) 14(22.6%)

When the effect of satisfaction with current insulin product used was examined on the
preference for inhaled insulin, a higher percentage of unsatisfied patients seemed to prefer
inhaled insulin. There was a statistically significant relationship between satisfaction with
syringe/vial insulin and the preference for inhaled insulin (χ2=13.192, df=1, p <. 001). A higher
percentage of patients not satisfied in comparison to those who were satisfied with their current
insulin products, preferred inhaled insulin (Table IX). These results were found to be in
agreement with previous findings, where patients with high HbA1c values (as a result of poor
adherence with insulin therapy) were less satisfied (Anderson et al., 2004).

Table IX: The effect of satisfaction with current insulin product used on preference for
inhaled insulin
Satisfaction
Syringe/vial insulin*
Pen insulin

Preference for inhaled insulin
No
Yes
29(63.0%)
17(37.0%)
61(91.0%)
6(9.0%)
21(67.7%)
10(32.3%)
82(77.4%)
24(22.6%)

No
Yes
No
Yes

*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the
preferences for inhaled insulin with the level of satisfaction with syringe/vial insulin at p < 0.001 significance level.
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Product attribute measures
The product attribute measures were explored in a 2-step process. First, the patients were
asked to rate the importance of each item under four product attributes. Second, the patients were
asked to rate the performances of three insulin products on those items after reading product
profiles. Table X shows the importance of product attributes from the perspective of Type 2
diabetic patients, captured in the form of importance of achieving various goals of the insulin
therapy. Since the product attribute importance means were very high (along with small standard
deviations), the 7-point Likert type scale was also explored as a dichotomous variable (“Very
high importance” – importance rating 6 and above, and “Medium importance” – importance
rating below 6).
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Table X: Mean importance ratings for perceived importance of various product attribute
measures
Product attribute items
Control blood sugar levels to goal levels
Keeping your blood sugar levels stable
Fasting blood sugar levels to goal levels
Post-prandial glucose levels to goal
levels
Clinical Efficacy
Avoiding Symptoms of low blood sugar
or hypoglycemia
Reducing the possible side effects of
insulin medication, like allergic
reactions
Minimizing weight gain from insulin
therapy
Safety
Flexibility in time required between
insulin dose and eating
Minimizing the frequency of monitoring
blood sugar with finger-stick test
Convenient for me to carry with me
during the day
Making it easy to take insulin in a public
place
Reducing the pain or discomfort of
taking insulin
Making it easy to accurately measure the
correct dose of insulin
Convenience
Selecting the best product I can afford
Selecting the products with the lowest
out-of-pocket cost
Selecting a product that I can afford
Cost

Average importance
ratings (Std Dev)*
6.38 (0.90)
6.34 (0.92)
5.96 (1.05)
5.81 (1.08)

Percentage of patients in
top 2 boxes (6 & 7)**
406 (91.9%)
394 (89.4%)
338 (75.7%)
304 (67.5%)

6.12 (0.85)
6.36 (1.00)

396 (89.6%)

6.00 (1.16)

338 (75.9%)

6.16 (1.07)

359 (80.5%)

6.17 (0.90)
5.71 (1.15)

276 (62.3%)

5.56 (1.22)

252 (57.1%)

5.74 (1.30)

298 (68.3%)

5.39 (1.49)

244 (56.1%)

5.58 (1.39)

263 (58.8%)

6.19 (1.08)

374 (83.2%)

5.70 (0.99)
5.92 (1.34)
5.53 (1.53)

340 (76.6%)
264 (59.8%)

5.79 (1.46)
5.75 (1.34)

317 (70.6%)

*Mean ± SD (range) importance ratings on a 7 point Likert type scale.
**Represents the percentage of patients who reported an item to be of very high importance (i.e., marked 6 or 7 on a
7-point scale).
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The majority of items for clinical efficacy and safety had a high mean importance, which
shows that diabetic patients consider clinical attributes (efficacy and safety of drug products) to
be more important in comparison to convenience and cost of the insulin product. “Controlling
blood sugar levels to goal levels” was reported to be the most important factor with a mean of
6.38 (on a 7-point scale), whereas “Making it easy to take insulin in a public place” was found to
be least important item with a mean of 5.39.
After examining the importance of product attributes, the performances of inhaled
insulin, syringe/vial insulin and pen insulin were explored on the same product attributes. Table
XI depicts the performance of insulin products on various treatment goals (categorized under
four product attributes). Overall, inhaled insulin was perceived to perform best under clinical
efficacy, safety, and convenience, followed by pen insulin and finally syringe/vial insulin,
whereas, for the cost of items, an opposite trend was seen with syringe/vial insulin considered
least expensive, followed by pen insulin and inhaled insulin.
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Table XI: Performance of inhaled, pen, and syringe insulin on product attribute measures
Product attributes
Control blood sugar levels to goal
levels
Clinical
efficacy

Safety

Convenience

Keeping your blood sugar levels stable
Fasting blood sugar levels to goal
levels
Post-prandial glucose levels to goal
levels
Avoiding Symptoms of low blood
sugar or hypoglycemia
Reducing the possible side effects of
insulin medication, like allergic
reactions
Minimizing weight gain from insulin
therapy
Flexibility in time required between
insulin dose and eating
Minimizing the frequency of
monitoring blood sugar with fingerstick test
Convenient for me to carry with me
during the day
Making it easy to take insulin in a
public place
Reducing the pain or discomfort of
taking insulin
Making it easy to accurately measure
the correct dose of insulin
Selecting the best product I can afford

Cost

Selecting the products with the lowest
out-of-pocket costs
Selecting a product that I can afford

*Mean ± SD (range) importance ratings out of 7.
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Inhaled
insulin*
6.29
(1.626)
6.24
(1.562)
6.43
(1.533)
6.39
(1.617)
6.05
(1.776)

Pen
insulin*
6.06
(1.147)
5.66
(1.368)
6.18
(1.417)
6.16
(1.424)
5.56
(1.410)

Syringe
insulin*
5.66
(1.578)
5.52
(1.578)
6.01
(1.634)
6.05
(1.590)
5.29
(1.613)

6.44
(1.319)

5.13
(1.698)

4.74
(1.869)

5.50
(2.090)
6.16
(1.536)

5.09
(2.005)
5.52
(1.482)

4.93
(2.054)
5.12
(1.709)

6.24
(1.752)

5.88
(1.728)

5.60
(1.940)

6.42
(1.193)
6.42
(1.230)
6.60
(1.092)
6.29
(1.466)
5.30
(1.920)
4.64
(2.061)
5.17
(1.967)

6.02
(1.193)
5.45
(1.398)
4.93
(1.584)
6.31
(1.058)
5.79
(1.439)
5.86
(1.394)
6.01
(1.363)

3.86
(1.957)
3.58
(1.843)
3.83
(1.915)
4.87
(1.804)
5.75
(1.592)
6.12
(1.339)
6.12
(1.318)

The summated scale score variables were derived from product performance ratings
based on the criteria described in Chapter 3, page 23. Table XII shows the percentage
distribution of diabetic patients who defined inhaled insulin to be worse, undifferentiated, or
better in comparison to pen insulin and syringe/vial insulin. A similar trend was observed in both
the comparisons, with inhaled insulin being perceived better in comparison to pen and
syringe/vial insulin by the majority of diabetic patients (under efficacy, safety and convenience).
Even though pen insulin is thought to be a convenient method of taking insulin, inhaled insulin
was perceived to be better than pen insulin by 78.8% of patients. As far as cost was concerned,
inhaled insulin was perceived to be worse than both pen and syringe/vial insulin by 57.3% and
56.2% of patients, respectively. It was interesting to note that a group of patients still perceived
inhaled insulin to be better in cost (20.7% in comparison to pen insulin and 21.45% in
comparison to syringe/vial insulin). As expected, the majority of patients (87% for syringe vs.
78.9% for pen) perceived inhaled insulin to be better than syringe insulin and pen insulin in
convenience.

49

Table XII: Cross-tabs results of product differentiation on product attributes
% of patients
Inhaled compared to Inhaled compared to
pen
needle/syringe
18.8%
17.8%
22.6%
20.5%
58.6%
61.7%
15.1%
13.7%
19.0%
18.4%
65.8%
67.9%
11.6%
4.1%
9.5%
8.9%
78.9%
87.0%
57.1%
56.1%
22.2%
22.4%
20.7%
21.5%

Product attributes

Clinical Efficacy

Safety

Convenience

Cost

Worse
Not differentiated
Better
Worse
Not differentiated
Better
Worse
Not differentiated
Better
Worse
Not differentiated
Better

Product Preferences
The preferences for insulin products in diabetic patients were captured at two levels.
First, the patients were asked to imagine if there was no difference in the out-of-pocket costs of
all three products; and, in the second situation, they were asked to consider the out-of-pocket
costs of the products as per their personal insurance coverages and information provided to them.
The product preferences are depicted in Table XIII.
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Table XIII: Descriptive for preferences of insulin products
Insulin naïve

Sample

Insulin users

Total

N

%

N

%

N

255

52.9%

227

47.1%

482

%

Product choice with no difference in cost*
Insulin needle

2

0.8%

18

7.9%

20

4.1%

Insulin pen

52

20.4%

70

30.7%

122

25.3%

Inhaled insulin

178

69.8%

100

43.9%

278

57.6%

No preference, will take

23

9.0%

40

17.5%

63

13.0%

whatever the doctor
prescribes
Actual product choice (considering cost difference)*
Insulin needle

8

3.1%

47

20.6%

55

11.4%

Insulin pen

92

36.1%

86

37.7%

178

36.9%

Inhaled insulin

123

48.2%

52

22.8%

175

36.2%

No preference, will take

32

12.5%

43

18.9%

75

15.5%

whatever the doctor
prescribes
Likelihood to use inhaled insulin on doctors recommendation*
Very unlikely

5

2.0%

15

6.6%

20

4.1%

Unlikely

3

1.2%

9

3.9%

12

2.5%

Undecided

24

9.4%

41

18.0%

65

13.5%

Likely

73

28.6%

52

22.8%

125

25.9%

Very likely

150

58.8%

111

48.7%

261

54.0%

Ask doctor for inhaled insulin*
Very unlikely

3

1.2%

10

4.4%

13

2.7%

Unlikely

8

3.1%

31

13.6%

39

8.1%

Undecided

76

29.8%

62

27.2%

138

28.6%

Likely

98

38.4%

85

37.3%

183

37.9%

Very likely

70

27.5%

40

17.5%

110

22.8%

*Comparisons based upon the Pearson chi-square statistics for column portions showed significant difference in the
preferences for inhaled insulin among two groups at p < 0.001 significance level.

51

Results indicate that inhaled insulin was the most preferred product (57.5%), when
patients were told to assume no difference in the out-of-pocket costs of the products. The product
preferences changed when the patients were asked to consider their monthly out-of-pocket costs
of the products, and insulin pen and inhaled insulin were found to be equally preferred products
(with 36.9% and 36.3%, respectively). When the two groups were compared for product choice
with no differences in cost, a higher percentage of insulin naïve patients than insulin users
preferred inhaled insulin. Even after considering the out-of-pocket costs, preference for inhaled
insulin was high among insulin naïve patients (48.2% insulin naïve vs. 22.8% insulin users).
Doctors’ recommendations seemed to influence patients’ decisions in both the groups and
overall, 60% of the patients were likely to ask their doctors to prescribe inhaled insulin.

Examination of research objectives
Objective 1: To examine patients’ perceptions about current injectable insulin in comparison to
inhaled insulin and to use these measures to predict their preferences for the new inhaled insulin
product.

Product attributes variables, and preference for inhaled insulin
After the summation of importance ratings for product attribute items, a mean importance
score for each attribute was created. Then the summated-scale scores were converted into a
dichotomous variable using the criteria: “Very high importance” – importance rating 6 and above
and “Medium importance” – importance rating below 6. Table XIV shows the results of
univariate logistic regression models, which were run in order to see if the patients who marked
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an attribute to be of “Very high importance” or “Medium importance”, were different from each
other in terms of their preferences for inhaled insulin.

Table XIV: Results of univariate logistic regression between perceived importance of
product attribute measures and preferences for inhaled insulin
Product attributes
Clinical Efficacy
Safety
Convenience
Cost

β

Sig.

OR

.207
.789
0.486
.156

.33
.001
.011
.424

1.23
2.202
1.626
1.169

95% C.I. for OR
Lower
Upper
.81
1.868
1.373
3.531
1.119
2.363
.797
1.714

Importance placed on safety (Wald = 10.717, p = 0.001) and convenience (Wald = 6.49,
p = 0.011) significantly predicted the preference for inhaled insulin. Based on odds ratio, the
patients were 2.2 and 1.63 times more likely to prefer inhaled insulin if they marked safety and
convenience of a product to be of high importance rather than medium importance.
A Pearson chi-square test was run to check the relationship of preference for inhaled
insulin with summated-scale score variables for the performances (on product attributes) of
inhaled versus competitive products. The performance comparison of inhaled insulin and pen
insulin on efficacy, safety and convenience had a statistically significant relationship with the
preference for inhaled insulin; whereas, for a performance comparison of inhaled and
syringe/vial insulin, all four product attributes had a statistically significant relationship with the
preference for inhaled insulin. Table XV provides the percentage of patients under “worse,” “not
differentiated,” and “better” categories for comparison of product performance that preferred
inhaled insulin. Except for the cost attribute, the majority of the patients prefer inhaled insulin
only if they perceived inhaled insulin to perform better than its competitors. This effect is most
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pronounced in the case of convenience, where the patients prefer inhaled insulin only if they
perceived it to be more convenient than its competitors.

Table XV: Percent of patients preferring inhaled insulin by categories “Worse,” “Not
differentiated,” and “Better” for performance on product attributes
Product attributes
Clinical Efficacy
Safety
Convenience
Cost

Inhaled insulin vs. pen insulin
Inhaled vs. syringe/vial insulin
Worse Not differentiate Better Worse Not differentiate Better
2.9%
7.5%
25.9% 4.1%
6.2%
25.9%
2.5%
5.0%
28.8% 2.5%
4.1%
29.6%
0.8%
1.9%
33.5% 0.4%
1.2%
34.6%
20.1%
8.1%
8.1% 17.6%
8.3%
10.4%

Pearson Chi-square tests for column proportions with preference for inhaled insulin as dependent variable and
product differentiation on performance of competing products as independent variables. Shaded regions depict
statistically significant results at p < .001 for safety, efficacy, and convenience in both the comparisons; at p < 0.05
for cost in inhaled vs. syringe/vial comparison.

Multivariable Logistic Regression
In order to predict the preference for inhaled insulin, 2 multivariable logistic regressions
were run using four summated-scale score variables each for performance comparisons of
inhaled insulin vs. pen insulin, and inhaled insulin vs. syringe/vial insulin. The results obtained
have been mentioned in Table XVI below.
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Table XVI: Multivariable logistic regression results when patients’ preferences for inhaled
insulin is the dependent variable

Clinical Efficacy
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Safety
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Convenience
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Cost
(1) Worse
(2) Not differentiated
(Ref)
(3) Better

Inhaled vs. pen insulin
Sig.
OR
95% C.I. for OR
.036
.033 0.41
(.181-.931)

Inhaled vs. syringe/vial insulin
Sig
OR
95% C.I. for OR
.6
.316 .673
(.31-1.459)

.802
.173
.695

1.075

(.611-1.891)

.871

(.485-1.567)

1.21

(.466-3.142)

.645
.019
.836

1.1

(.424-2.889)

.083
.001
.297

1.817

(.926-3.566)

2.356

(1.166-4.759)

0.485

(.125-1.889)

.017
.019
.673

1.487

(.236-9.387)

.029
.083
.073

2.873

(1.115-7.4)

4.032

(1.395-11.655)

.591

(.333-1.05)

.01
.006
.004

.433

(.245-.766)

.028

.465

(.235-.92)

.313

.715

(.373-1.372)

With the help of multivariable logistic regression, the strongest drivers of preference for
inhaled insulin were observed for two comparisons: inhaled insulin versus pen insulin and
inhaled insulin versus syringe/vial insulin. When inhaled insulin was compared to pen insulin,
performance differentiation (based on summated-scale score variables for performance) on
efficacy and convenience demonstrated a statistically significant relationship with the preference
for inhaled insulin. When the products were compared for their performances on efficacy, the
odds ratio demonstrated that the respondents for whom the inhaled insulin performed “worse”
compared to those for whom inhaled insulin was “not differentiated” from pen insulin, were
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significantly less likely to prefer inhaled insulin. Whereas in the case of convenience, the
respondents who rated inhaled insulin to be “better than” in comparison to “not differentiated”
from pen insulin, were 2.8 times more likely to prefer inhaled insulin.
Similarly, when inhaled insulin was compared to syringe/vial insulin, performance
differentiation on safety, convenience, and cost demonstrated a statistically significant
relationship with the preference for inhaled insulin. Product comparison on safety and
convenience revealed that the patients, who rated inhaled insulin as “better than” in comparison
to “not differentiated” with syringe/vial, were 2.3 and 4 times, respectively, more likely to prefer
inhaled insulin. Patients, who rated the cost attribute of inhaled insulin to be “worse than” in
comparison to “not differentiated” from syringe/vial, were significantly less likely to prefer
inhaled insulin.

Objective 2: To explore differences in the insulin users and insulin naïve (not taking insulin)
diabetic patients in terms of value drivers for the new inhaled insulin product.

Apart from exploring the value drivers of inhaled insulin in Type 2 diabetic patients, the
second objective of this study was to examine and compare these value drivers in insulin and
non-insulin user sub-groups of the Type 2 diabetic sample. In order to meet with this objective,
the two groups (insulin naïve and insulin-using diabetic patients) were explored for differences
in their perceptions about importance of product attributes, product differentiation based on the
performance of product attributes and their preferences for inhaled insulin.
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Importance of product attributes – Group differences
The differences between two groups in terms of importance of attributes were explored
based upon the Pearson chi-square statistics for column proportions and the independent sample
t-tests for column means. Column proportions for importance attributes were examined at two
levels, “Medium importance” (for those who marked the importance of an item less than 6 on a
7-point Likert type scale) and “High importance” (for those who marked it more than or equal to
6 on a 7-point Likert type scale). Based on Pearson chi-square tests, a higher percentage of
patients in the insulin-naïve group compared to the insulin-using group placed high importance
on the clinical efficacy, safety and convenience of an insulin product. As far as importance of
cost of a product was concerned, both groups were similar. In terms of group means, independent
sample t-tests revealed statistically significant difference among the 2 groups on safety and
convenience.
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Table XVII: Differences in the perceptions of insulin-naïve and insulin-using patients based
on the importance that they place on product attributes
Insulin naïve
Product attributes

Insulin users

Importance

Percentage of

Importance

Percentage of

ratings

patients in top 2

ratings

patients in top 2

boxes (6 & 7)
Control blood sugar levels to

boxes (6 & 7)

6.38(0.93)

236(92.5%)

6.38(0.86)

208(91.2%)

6.39(0.88)

235(92.2%)

6.28(0.95)

197(86.4%)

5.94(0.99)

195(76.5%)

5.93(1.09)

171(75.0%)

5.95(0.99)

190(74.5%)

5.64(1.21)

136(59.6%)

Clinical Efficacy*

6.17(0.83)

196(76.9%)

6.06(0.88)

150(65.8%)

Avoiding Symptoms of low

6.42(0.92)

234(91.8%)

6.28(1.09)

199(87.3%)

6.21(1.00)

214(83.9%)

5.76(1.28)

153(67.1%)

6.27(0.95)

216(84.7%)

6.04(1.19)

173(75.9%)

Safety*#

6.30(0.82)

208(81.6%)

6.03(0.98)

156(68.4%)

Flexibility in time required

5.88(1.06)

178(69.8%)

5.51(1.22)

123(53.9%)

5.59(1.21)

153(60.0%)

5.54(1.23)

123(53.9%)

5.86(1.19)

189(74.1%)

5.62(1.40)

141(61.8%)

5.52(1.35)

152(59.6%)

5.24(1.63)

119(52.2%)

goal levels
Keeping your blood sugar
levels stable*
Fasting blood sugar levels to
goal levels
Post-prandial glucose levels to
goal levels*#

blood sugar or hypoglycemia
Reducing the possible side
effects of insulin medication,
like allergic reactions*#
Minimizing weight gain from
insulin therapy*#

between insulin dose and
eating*#
Minimizing the frequency of
monitoring blood sugar with
finger-stick test
Convenient for me to carry
with me during the day*#
Making it easy to take insulin
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in a public place#
5.82(1.24)

171(67.1%)

5.32(1.52)

113(49.6%)

6.32(0.98)

227(89.0%)

6.04(1.17)

175(76.8%)

Convenience*#

5.83(0.89)

139(54.5%)

5.54(1.07)

97(42.5%)

Selecting the best product I can

5.94(1.28)

198(77.6%)

5.91(1.39)

172(75.4%)

5.50(1.50)

148(58.0%)

5.56(1.57)

141(61.8%)

5.89(1.33)

188(73.7%)

5.67(1.59)

153(67.1%)

5.78(1.26)

154(60.4%)

5.71(1.42)

141(61.8%)

Reducing the pain or
#

discomfort of taking insulin*
Making it easy to accurately
measure the correct dose of
insulin*#

afford
Selecting the products with the
lowest out-of-pocket costs
Selecting a product that I can
afford
Cost

Comparisons based upon the Pearson chi-square* statistics for column proportions and the t-test# for column means
showed significant difference in the importance of product attribute in two groups at p < 0.05 significance level.

Performance of competing products on product attributes – Group differences
The percentage distribution of diabetic patients who defined inhaled insulin to be worse,
undifferentiated, or better in comparison to pen insulin was explored in both insulin-user and
insulin naïve sub-groups.
A similar trend was observed in both the sub-groups, with inhaled insulin performing
better than pen and syringe/vial insulin in efficacy, safety, and convenience. The two subgroups
were significantly different in terms of product differentiation on cost attribute, where a higher
number (63.1% for inhaled vs. pen, and 60% for inhaled vs. syringe/vial) of patients in the
insulin-naïve than in the insulin-user group (50.4% for inhaled vs. pen, and 51.8% for inhaled vs.
syringe/vial) rated inhaled insulin to be worse than its competitors (both pen insulin and
syringe/vial insulin). The two comparisons (inhaled insulin vs. pen and inhaled insulin vs.
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syringe) had similar distributions, except for convenience. The majority of patients in both the
sub-groups of the diabetic sample found inhaled insulin to be better than syringe/vial for
convenience.

Table XVIII: Cross tab results for product differentiation to explore differences among
insulin naïve and insulin using patients.
Product attributes
Efficacy - inhaled
vs. pen

Safety – inhaled vs.
pen

Convenience –
inhaled vs. pen

Cost – inhaled vs.
pen

Efficacy - inhaled
vs. syringe

Safety – inhaled vs.
syringe

Convenience –
inhaled vs. syringe

Cost – inhaled vs.
syringe

Insulin naïve

Insulin using

Worse

44(17.3%)

47(20.6%)

Not differentiated

55(21.6%)

54(23.7%)

Better

156(61.2%)

127(55.7%)

Worse

36(14.1%)

37(16.2%)

Not differentiated

45(17.6%)

47(20.6%)

Better

174(68.2%)

144(63.2%)

Worse

30(11.8%)

26(11.4%)

Not differentiated

20(7.8%)

26(11.4%)

Better

205(80.4%)

176(77.2%)

Worse

161(63.1%)

115(50.4%)

Not differentiated

57(22.4%)

50(21.9%)

Better

37(14.5%)

63(27.6%)

Worse

40(15.7%)

46(20.2%)

Not differentiated

54(21.2%)

45(19.7%)

Better

161(63.1%)

137(60.1%)

Worse

31(12.2%)

35(15.4%)

Not differentiated

41(16.1%)

48(21.1%)

Better

183(71.8%)

145(63.6%)

Worse

8(3.1%)

12(5.3%)

Not differentiated

17(6.7%)

26(11.4%)

Better

230(90.2%)

190(83.3%)

Worse

153(60.0%)

118(51.8%)

Not differentiated

59(23.1%)

49(21.5%)

Better

43(16.9%)

61(26.8%)
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Sig (2-sided)

.455

.501

.412

.001

.435

.157

.082

.029

Product attribute variables and preference for inhaled insulin
With the help of univariable logistic regression, the relationship between importance
variables for product attributes and preference for inhaled insulin was examined. Table XIX
shows the result of univariable logistic regression for the insulin-user sub-group and insulinnaïve sub-group of diabetic patients, respectively.
In insulin users, importance placed on safety (Wald = 4.588, p = 0.032), and convenience
(Wald = 7.785, p = 0.005) significantly predicted the preference for inhaled insulin. Based on
odds ratio, the patients were 2.28 and 2.46 times more likely to prefer inhaled insulin if they
marked safety and convenience of a product to be of high importance in comparison to low
importance.

Table XIX. Results of univariate logistic regression models between perceived importance
of product attribute measures and preference for inhaled insulin
Product attributes
Clinical Efficacy
Safety
Convenience
Cost

OR
1.092
2.284
2.46
1.52

Insulin users
95% C.I. for OR
(0.56-2.1)
(1.07-4.86)
(1.3-4.63)
(0.78-2.95)

OR
1.04
1.642
1.06
1.048

Insulin naïve
95% C.I. for OR
(0.58-1.86)
(0.86-3.13)
(0.65-1.74)
(0.63-1.73)

Shaded regions depict statistically significant differences at p < 0.05 level.

When univariable logistic regression was conducted for insulin naïve patients, none of
the product attributes significantly predicted their preference for inhaled insulin.
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The results of chi-square tests between performance comparisons and preference for
inhaled insulin are described in Table XX. Among insulin users, when inhaled insulin was
compared with pen insulin, a statistically significant relationship was found between the
preference for inhaled insulin and performance of efficacy and safety; whereas, when inhaled
insulin was compared against syringe/vial insulin, a statistically significant relationship was
found between the preference for inhaled insulin and performance of safety. When similar tests
were run among insulin-naïve patients, the performances of comparative products on all the four
product attributes had a statistically significant relationship with the preference for inhaled
insulin. Considering the results from Table XIX, it seems like for the insulin-naïve subgroup of
diabetic patients, the performance of products is more important than achieving specific goals in
their product-selection criteria.

Table XX. Categorical summated-scale score variables for performance of insulin products
vs. preference for inhaled insulin among insulin-user and insulin-naïve diabetic patients
Product attributes
Efficacy
Safety
Convenience
Cost
Efficacy
Safety
Convenience
Cost

Inhaled insulin vs. pen insulin
Inhaled vs. syringe/vial insulin
Worse Not differentiate Better Worse Not differentiate Better
Insulin users
1.8%
5.7%
15.4% 3.5%
4.4%
14.9%
1.3%
3.5%
18.0% 1.3%
3.1%
18.4%
0.9%
1.8%
20.2% 0.4%
1.3%
21.1%
12.7%
4.8%
5.3% 10.1%
5.3%
7.5%
Insulin naïve
3.9%
9.0%
35.3% 4.7%
7.8%
35.7%
3.5%
6.3%
38.4% 3.5%
5.1%
39.6%
0.8%
2.0%
45.5% 0.4%
1.2%
46.7%
26.7%
11.0%
10.6% 24.3%
11.0%
12.9%

Pearson Chi-square tests for column proportions with preference for inhaled insulin as dependent variable and
product differentiation on performance of competing products as independent variables. Shaded columns represent
statistically significant differences between the product differentiation and preference of inhaled insulin at p < 0.05
(light shade), and p < 0.001 (dark shade).
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Multivariable logistic regression
The results obtained from the multivariable logistic regression for the insulin-user subgroup of diabetic patients can be seen in Table XXI. In this subgroup of patients, we found that
none of the summated-scale score variables for performance of competing products significantly
predicted the preference of inhaled insulin.

Table XXI. Multivariable logistic regression results for insulin-user diabetic patients when
preference to use inhaled insulin is the dependent variable

Efficacy
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Safety
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Convenience
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Cost
(1) Worse
(2) Not differentiated
(Ref)
(3) Better

Inhaled vs. pen insulin
OR
Sig.
95% C.I. for OR
.207
.106 .317
(.079-1.275)

Inhaled vs. syringe/vial insulin
Sig
OR
95% C.I. for OR
.5
.681 .774
(.228-2.629)

.93
.139
.873

.959

(.377-2.441)

.556

(.203-1.525)

.875

(.169-4.532)

.255
.071
.618

.652

(.121-3.505)

.114
.558
.842

2.398

(.811-7.091)

2.71

(.85-8.636)

.812

(.105-6.298)

.092
.416
.655

1.852

(.125-25.517)

.477
.07
.823

1.677

(.403-6.972)

2.721

(.55-13.474)

.896

(.344-2.338)

.22
.441
.185

.528

(.205-1.359)

.076

.353

(.111-1.116)

.419

.651

(.23-1.843)
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Further, the same model was run in the insulin-naïve sub-group of diabetic patients
(Table XXII). Here, performance of convenience, cost for inhaled vs. pen and cost performance
of inhaled vs. syringe were found to have statistically significant relationships with the
preference for inhaled insulin. When inhaled insulin was compared to pen insulin, the
respondents who rated inhaled insulin on convenience “better than” in comparison to those who
rated it ‘not differentiated’ from pen insulin were 4.1 times more likely to prefer inhaled insulin.
For the cost performance in both product comparisons, the respondents who rated inhaled insulin
to be “worse” in comparison to “not differentiated” from pen insulin were significantly less
likely to prefer inhaled insulin.
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Table XXII. Multivariable logistic regression results for insulin-naïve diabetic patients
when preference to use inhaled insulin is the dependent variable

Efficacy
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Safety
(1) Worse
(2) Not differentiated
(Ref)
(3) Better
Convenience
(4) Worse
(1) Not differentiated
(Ref)
(2) Better
Cost
(1) Worse
(2) Not differentiated
(Ref)
(3) Better

Inhaled vs. pen insulin
Sig.
OR
95% C.I. for OR
.215
.138 .435
(.145-1.307)

Inhaled vs. syringe/vial insulin
Sig
OR 95% C.I. for OR
.383
.385
.629
(.221-1.791)

.937
.569
.586

.652
.203
.556

1.189

(.561-2.52)

1.472

(.406-5.334)

.09
.081
.958

2.336

(.876-6.234)

.931

(.065-13.399)

4.134

(.926-18.443)

.393

(.181-.853)

1.778

(.655-4.825)

1.03

(.482-2.207)

1.436

(.39-5.281)

.288
.001
.244

1.665

(.65-4.266)

.326

(.049-2.152)

.035
.011
.034

4.156

(1.109-15.58)

.425

(.193-.937)

.063
<.001
.018

.657

1.263

(.452-3.53)

.258
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CHAPTER V – DISCUSSION

This study presents a unique methodology for not only exploring the potential value
drivers for a new pharmaceutical product, but also for developing strategic insights to aid
pharmaceutical companies in making critical decisions regarding product promotion. In
pharmaceutical marketing, the product preference and decision analytic approaches are
commonly used to compare new drug products with their competitors. However, using the
SVDM approach not only identifies key value drivers, but also provides strategic insights into
the value drivers that can be used to develop marketing strategies.
Prior research suggests that convenience issues of insulin treatment like flexibility of
treatment, social comfort, ease of use and reduced pain from injections are important issues for
insulin-user diabetic patients (Testa & Simonson 2007; Kadiri et al., 1998). However, research in
the area of preference for insulin products has not focused on all the attributes of a product and
for the most part, differences in the products were based on the convenience and ease of use of
the insulin products (Testa & Simonson, 2007; Pinto et al., 2009; Rosenstock et al., 2004).
Therefore, the main objective of this study was to examine the role of product attributes in the
decision to purchase inhaled insulin. The product attributes were examined from a marketing
standpoint as it will be critical for the manufacturer of new inhaled insulin to measure patients’
perceptions about the product and identify ways to effectively differentiate the new product from
traditionally available insulin products.
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Importance of product attributes measures
Results indicated that diabetes patients’ considered clinical efficacy and safety of the
insulin products to be very important. Insulin users and insulin-naïve patients were significantly
different from each other in terms of the amount of importance they placed on clinical efficacy,
safety, and convenience. A higher percentage of insulin naïve patients placed high importance on
clinical efficacy, safety and convenience than insulin-user patients (76.9% vs. 65.8% for
efficacy, 81.6% vs. 68.4% for safety, and 54.5% vs. 45.2% for convenience, respectively)
(Figure IV). As far as importance of cost of a product was concerned, both the groups were
similar.

Figure IV: Difference in the perception of insulin naïve and insulin using patients based on
the importance that they place on product attributes
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In type 2 diabetic patients, stated importance for safety (Wald = 10.717, P = 0.001), and
convenience (Wald = 6.49, P = 0.011) significantly predicted the preference for inhaled insulin.
Interestingly, in the insulin-user subgroup, safety and convenience significantly predicted the
preference for inhaled insulin; in contrast, in the insulin-naïve subgroup, stated importance of
product attributes did not predict the preference for inhaled insulin. This indicates that in insulinnaïve patients, preference for inhaled insulin is primarily driven by the performance of products
rather than the importance of achieving specific treatment goals. This piece of information could
be used by the manufacturer of a new inhaled insulin product in targeting insulin-naïve patients
and promoting better performance of a new product (in comparison to its competitors) rather
than teaching them about the importance of achieving various insulin treatment goals via DTCA
(Direct To Consumer Advertisements). On the other hand, if our target is the insulin-user
subgroup, better safety and convenience of the new product should be promoted.

Performance on product attributes
When inhaled insulin was compared to pen insulin, convenience was found to be the
major value driver for the preference of inhaled insulin. 78.8% of the patients perceived inhaled
insulin to be better than the pen for convenience, and 33.5% of patients who preferred inhaled
insulin were from this category (Figure V). Similarly, when comparing inhaled insulin with
syringe/vials for convenience, 86.9% of the patients perceived inhaled insulin’s performance to
be better than syringe/vial, and 34.6% of patients who preferred inhaled insulin were from this
category (Figure VI). Additionally, the results indicated that patients are going to prefer inhaled
insulin only if they perceive it to be better (in comparison to the “not differentiated” and “worse”
categories) in convenience than its competitors. Therefore, the new inhaled insulin should be
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promoted as a more convenient insulin product in comparison to pen insulin. Specifically, the
convenience items with high stated importance, like “making it easy to accurately measure the
correct dose of insulin”, “convenient for me to carry with me during the day,” and “flexibility in
time required between insulin doses and eating” should be focused on. As far as safety and
efficacy attributes were concerned, the majority of patients who preferred inhaled insulin came
from the group of patients that perceived inhaled insulin to perform better in these attributes than
its competitors. In contrast, perceived performance of cost provided slightly different results.
We observed that patients who preferred inhaled insulin over other products often rated inhaled
insulin as worse on cost. This indicates that for some patients, convenience and other product
performance attributes are more important than cost.

Performance of inhaled vs. pen

Preference for inhaled

Worse
Undifferentiated

% of patients

Cost

Convenience

Safety

Efficacy

Cost

Convenience

Better
Safety

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Efficacy

% of patients

Figure V: Comparing product differentiation among inhaled insulin and pen insulin with
preference for inhaled insulin

% of patients who preferred
inhaled insulin
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Figure VI: Comparing product differentiation among inhaled insulin and syringe/vial
insulin with preference for inhaled insulin
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Multivariable logistic regression was used to identify the strongest drivers of preference
of inhaled insulin. Performance of clinical efficacy and convenience were the strongest
predictors of preference for inhaled insulin when inhaled insulin was compared against pen
insulin. However, when inhaled insulin was compared with syringe/vial insulin, performance of
safety, convenience and cost were strong predictors of preference for inhaled insulin.
When the similar analysis was run for two subgroups, i.e., insulin naïve and insulin users,
we found interesting results. Among insulin-naïve patients, performance of convenience and cost
were significant predictors for preference of inhaled insulin when inhaled insulin was compared
to pen insulin; whereas performance of cost alone was the significant predictor for preference of
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inhaled insulin when inhaled insulin was compared to syringe/vial insulin. Interestingly, among
insulin users none of the product performance comparisons significantly predicted preference for
inhaled insulin. This effect may be attributable to the following reasons: (1) the decision making
of insulin users may depend to a certain extent on the performance of all the product attributes,
or (2) the percentage of insulin users that preferred inhaled insulin was very low, which may
have resulted in diminished effects. Therefore, from product promotion standpoint, it may prove
valuable to decide whether it is cost effective to target insulin users at all or to focus only on
insulin-naïve patients (48.2% of insulin-naïve patients as compared to 22.8% of insulin-user
preferred inhaled insulin).

Product Preference
When the patients were asked to assume no difference in the cost of the products, inhaled
insulin was the most preferred product (57.5%). However, introduction of the cost for inhaled
insulin significantly reduced product preference. We found that inhaled insulin and insulin pen
were equally preferred products (36.9% and 36.3%, respectively). Furthermore, the comparison
of two subgroups indicated that a higher percentage of insulin-naïve patients, in comparison to
insulin-user, preferred inhaled insulin. On exploring the preferences at these two levels, with
introduction of cost, we observed that some insulin-naïve patients switched to the insulin pen,
while insulin users switched to insulin syringe/vials.
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Figure VII: Product preferences of Type 2 diabetic patients with no difference in the cost of
the products
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Figure VIII: Product preferences of Type 2 diabetic patients on considering out-of-pocket
monthly cost of the products
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Strategy development for the promotion of new inhaled insulin product
Due to the complex nature of the US health care system, where the decision to adopt a
new drug product depends on a wide gamut of factors, it becomes critical for the manufacturer to
develop effective strategies for promoting a new product. The results obtained from this study
could be used to understand the dynamics of the diabetes market and will also help the
manufacturers identify the group of diabetic patients that would be more likely to prefer the new
product.
The stated and derived importance of product attributes allow us to infer that out of four
product attributes, clinical efficacy and safety were very important for diabetic patients; and
based on the information provided to them (along with their prior knowledge of diabetes), the
majority of them perceived inhaled insulin to perform better than its competitor. Hence, it would
be critical to differentiate the new drug product on clinical efficacy and safety from its
competitors while promoting inhaled insulin. Promoting better efficacy and safety profiles of
inhaled insulin would be more beneficial because traditionally available insulin products, i.e., the
insulin syringe and insulin pen, are similar in terms of efficacy and safety. Overall, the
convenience attribute was less important than clinical efficacy and safety, but the new inhaled
insulin was perceived to be best among its competitors (in terms of convenience). Therefore, it
would be important for the manufacturer to promote the convenience of the new inhaled insulin
product. The payoff (in terms of preference for inhaled insulin) was found to be approximately
50% in the case of each product attribute, which could be due to an overlap of product
differentiation (e.g., inhaled insulin might be perceived to perform better in one attribute, but not
in another attribute, which might be more important to this particular patient) or some unknown
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concerns (or unmeasured factors in this study) from the patients’ perspectives in adopting a new
drug product.
Patient co-pays or out-of-pocket costs have been significant barriers when it comes to
adoption of new drug products. Even though, various studies confirmed greater satisfaction with
the use of Exubera (inhaled insulin that was developed and marketed by Pfizer and recalled in
2007), with the majority of patients preferring it over injectable insulin, a recent study found that
the amount that diabetic patients were willing to pay for Exubera was approximately equal to
what they were paying for their traditional insulin therapy (Pinto et al., 2009; Rosenstock et al.,
2004; Cappelleri, Cefalu, Rosenstock, Kourides, & Gerber, 2002; Freemantle et al., 2005).
Although the inhaled insulin product examined in these studies was different, cost was still found
to be a major barrier in the adoption of new inhaled insulin. The results from our study confirm
that cost indeed plays a major role, even if the new product is perceived to be better than its
competitors in not only convenience but also safety and efficacy profiles. However, we observed
a group of patients who classified cost of inhaled insulin to be worse than its competitors but still
preferred inhaled insulin over injectable insulin. A possible explanation for this could be that: (1)
this group of patients is cost insensitive, and they are willing to pay higher for a product with
better overall perceived value (which could be from better convenience or safety of inhaled
insulin), or (2) this group of patients includes a higher number of insulin-naïve patients (70.1%
in inhaled vs. pen and 72.94% in inhaled vs. syringe/vial comparisons).
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Figure IX: Product differentiation for cost-insensitive patients among inhaled insulin and
syringe/vial insulin with preference for inhaled insulin
Cost insensitive group in inhaled vs. pen comparison
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Figure X: Product differentiation for cost-insensitive patients among inhaled insulin and
syringe/vial insulin with preference for inhaled insulin
Cost insensitive group in inhaled vs. syringe comparison
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Therefore, it will be critical for the manufacturer of new inhaled insulin to develop some
strategies to minimize out-of-pocket cost as a barrier, either in terms of rebates and placing the
product on the 2nd or 3rd tier in health-care plans, or providing diabetic patients who are new to
insulin therapy with coupons of new inhaled insulin.
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Limitations of the study
Since a higher percentage of diabetic patients use pen insulin in Europe and the UK in
comparison to the US, expanding this study outside of the US may provide different information
on value drivers for inhaled insulin. Also, the methodology (SVDM) used for this study needs
further validation in different settings (e.g., study sample and products compared). Derivation of
summated-scale score variables for performance differentiation may have resulted in the loss of
information, specifically the accuracy and extent to which a product performed (“Worse” or
“Better”) on an attribute in relation to its competitor. Furthermore, as with any cross-sectional
study, this study did not provide evidence for causal relationships between the variables.
The use of an online panel of diabetic patients may have resulted in selection bias, since
internet users might be more educated and knowledgeable about diabetes in general. In addition,
the way that information about the products was revealed to the patients in the online survey
might not replicate the natural learning process of the patients, which may have influenced the
results in the process.
A major limitation that was identified for this study is that almost all of the insulin-user
patients had prior experience with Exubera. Future research is required to examine insulin-user
diabetic patients with no prior experience with Exubera. Also, since our study sample included
only Type 2 diabetic patients, the results could not be generalized to Type 1 diabetic patients.
Future research should explore value drivers of inhaled insulin in Type 1 diabetic patients.
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Thank you for being a part of this important research pertaining to diabetes. You will be asked to
read a short story and then respond to a group of questions about diabetes medication. Your
thoughtful responses are very important to us. Several others have been invited to share their
thoughts with us on this topic as well.

Although the information collected as a result of this project may be shared in presentations and
publications, your individual responses are confidential and will not be shared with anyone outside
the university research team. As there is no right or wrong answer to any item, please respond to
each item according to how you feel about your diabetes at this point in time. I appreciate your
taking the time to complete the survey. We anticipate the survey will take between 10-15 minutes
to complete.

Your participation in this study is voluntary. Your choosing not to participate will not affect your
relationship with The University of Mississippi. This study has been reviewed by The University of
Mississippi’s Institutional Review Board (IRB). The IRB has determined that this study fulfills the
human research subject protections obligations required by state and federal law and University
policies. If you have any questions, concerns, or reports regarding your rights as a participant of
this research, please contact the IRB at 662-915-7482.

Clicking >> (next) means that you are consenting to participate in this research project.
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Section I - Diabetes screener

1.

Which of the following has your doctor diagnosed you with? Check all that apply.
ROTATE CHOICES EXCEPT (8)
High blood pressure
Diabetes or high blood sugar (DISQUALIFY IF DIABETES OR HIGH BLOOD SUGAR IS NOT
SELECTED)
Obesity/overweight
High cholesterol/hyperlipidemia
Depression
Asthma
COPD (chronic obstructive pulmonary disorder)
None of the above

2.

How is your current diagnosis of diabetes classified?
Type 2 (DISQUALIFY IF TYPQ 2 NOT SELECTED)
Type 1
Other
Don’t know

3.

For how many years have you had Type 2 diabetes?___ years

4.

What do you currently take for controlling your high blood sugar levels? Check all that apply.
Diet and exercise (DISQUALIFY IF B OR C NOT SELECTED)
Take medications by mouth (GO TO Q5)
Insulin injections/shots (GO TO Q6)
Insulin pump (DISQUALIFY IF B OR C NOT SELECTED)
Byetta or Victoza (DISQUALIFY IF B OR C NOT SELECTED)
Other (specify) ___________ (DISQUALIFY IF B OR C NOT SELECTED)

5.

Which of the following types of oral anti-diabetic medication(s) are currently taking? NOTE that the
combination drug products are listed under both categories; therefore, if you are using a combination
product, PLEASE check both categories. (Check ALL that apply)
Sulphonylureas (Dymelor or generic Acetohexamide, Diabinese or generic Chlorpropamide,Tolinase
or generic Tolazamide, Orinase or generic Tolbutamide, Amaryl or generic Glimepiride, Glucotrol or
generic Glipizide, DiaBeta or generic Glyburide, Duetact, Avandaryl, Metaglip, Glucovance)
Meglitinides (Starlix or generic Nateglinide, Prandin or generic Repaglinide, Prandimet)
Biguanides (Glucophage or generic Metformin, Metaglip, Avandamet, ActoPlusMet, Prandimet,
Janumet, Glucovance)
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Thiazolidinediones (Actos or generic Pioglitazone, Avandia or generic Rosiglitazone, Duetact,
Avandaryl, Avandamet, ActoPlusMet)
Alpha-glucosidease Inhibitors (Precose or generic Acarbose, Glyset or generic Miglitol)
DPP-4 Inhibitors (Januvia or generic Sitagliptin, Janumet)
(DISQUALIFY IF Q5 COUNT IS LESS THAN 2 AND IF DID NOT CHECK 3 IN Q4, OTHERWISE GO
TO Q15)

Section II – Qualified diabetic patients

6.

How do you inject insulin?
Use a pen device to inject insulin (GO TO 7)
Use an insulin needle/syringe (GO TO 8)
Use a pen sometimes and insulin needle/syringe other times
Other (please specify) _______ (GO TO 9)

7.

DISPLAY Q7 IF CHECKED 1 IN Q6
Have you ever used an insulin needle/syringe as a method for taking insulin
Yes
No

8.

DISPLAY Q8 IF CHECKED 2 IN Q6
Have you ever used pen devices as a method for taking insulin
Yes
No

9.

DISPLAY Q9 IF CHECKED 3 IN Q4
Have you ever used Exubera for taking insulin?
Yes
No

DISPLAY Q10 IF CHECKED 3 IN Q4
10. How long have you been taking insulin? ____ years

DISPLAY Q10 IF CHECKED 3 IN Q4
11. How many times during the day do you take the following types of insulin? (PLEASE enter ‘0’ if you do
not take a specific type)
Rapid/Short acting insulin (NovoLog OR Humalog OR Apidra OR Humulin R OR Novolin R): _____
Intermediate acting insulin (Humulin N OR Novolin N OR U-500): _____
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Long acting insulin (Lantus OR Levemir): _____
Premixed insulin (Humulin Mix 50/50 OR Humulin 70/30 OR Novolin 70/30 OR Humalog Mix 75/25
OR NovoLog Mix 70/30): ______

DISPLAY Q10 IF CHECKED 1 OR 3 IN Q6
12. How satisfied are you with the insulin needle/syringe that you are currently using to inject insulin?
Very dissatisfied (GO TO Q15)
Somewhat dissatisfied (GO TO Q15)
Not sure
Somewhat satisfied
Very satisfied

DISPLAY Q10 IF CHECKED 2 OR 3 IN Q6
13. How satisfied are you with the insulin pen that you are currently using to inject insulin?
Very dissatisfied (GO TO Q15)
Dissatisfied (GO TO Q15)
Neutral
Satisfied
Very satisfied

DISPLAY Q10 IF CHECKED 3 IN Q4
14. Please rate the amount of pain you experience from injections on a scale of 1 to 7, where 1 means ‘No
pain’ and 7 means ‘Worst possible pain’ when you take:

1 – “No
Pain”

2

3

4

5

6

7–
“Worst
Possible
Pain”

Not
Applicable

Insulin
needle/syringe

o

o

o

o

o

o

o

o

Insulin pen

o

o

o

o

o

o

o

o

DISPLAY IF Q15 IF CHECKED 1 OR 2 IN Q12 OR Q13
15. You said you were dissatisfied with your current method for injecting insulin. What are the probable
reasons for your dissatisfaction? (Check ALL that apply)
Hypoglycemia
Weight gain
Too expensive
Need to monitor blood sugar too often with finger-stick test
Not effective in controlling my blood sugar levels

87

Need to take too many doses/day
Inconvenient
Other (specify) ________

16. Do you currently have any type of insurance that pays all or part of your:

Diabetes medication (oral anti-diabetic drugs or
insulin)
Insulin devices (needles/syringes)

Yes
ο

No
ο

ο

ο

Don’t know
ο
ο

17. How well do you understand the importance of the following:

Not at all
important

Very
unimportant

Somewhat
unimportant

Neither
important
nor
unimportant

Somewhat
important

Very
important

Extremely
Important

HbA1c test (lab value for
overall sugar control) and
its meaning for a person
with diabetes

ο

ο

ο

ο

ο

ο

ο

Achieving the required
fasting (pre-meal) blood
glucose levels

ο

ο

ο

ο

ο

ο

ο

Achieving the required
post prandial (after meal)
blood glucose levels

ο

ο

ο

ο

ο

ο

ο

18. What was the result of your last HbA1c test (lab value for overall sugar control)?
< 7%
7 - 7.9%
8 – 8.9%
9 - 9.9%
> 10%
Don’t know (GO TO Q20)
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19. Based on the results of your last HbA1c test, your diabetes is in
Excellent control
Good control
Fair control
Poor control
Not sure
20. Indicate the value that you would consider satisfactory for your HbA1c? _____%

DISPLAY Q21 IF CHECKED 3 IN Q4
21. While selecting an insulin product for managing diabetes, how important is it to achieve each of the
following treatment goals? Please rate the important of each using the scale below:
(ROTATE ITEMS)
Not at all
important

Very
important

Somewhat
important

Neither
important
nor
unimportant

Somewhat
important

Very
important

Fasting (morning before breakfast)
blood sugar (glucose) levels to goal
levels

ο

ο

ο

ο

ο

ο

ο

Making it easy to take insulin in a
public place (where people might
see you)

ο

ο

ο

ο

ο

ο

ο

Convenient for me to carry with me
during the day

ο

ο

ο

ο

ο

ο

ο

Post prandial (after meal) glucose
levels to goal levels

ο

ο

ο

ο

ο

ο

ο

Control blood sugar (glucose)
levels to goal levels

ο

ο

ο

ο

ο

ο

ο

Flexibility in time required between
insulin doses and eating

ο

ο

ο

ο

ο

ο

ο

Selecting the best product I can
afford

ο

ο

ο

ο

ο

ο

ο

Minimizing weight gain from
insulin therapy

ο

ο

ο

ο

ο

ο

ο

Minimizing the frequency of
monitoring blood sugar (glucose)
with finger-stick test

ο

ο

ο

ο

ο

ο

ο

Making it easy to accurately
measure the correct dose of insulin
dose

ο

ο

ο

ο

ο

ο

ο

Avoiding symptoms of low blood
sugar or hypoglycemia (such as
sweating, trembling, dizziness,
blurred vision and fast heart beat)

ο

ο

ο

ο

ο

ο

ο

Reducing the possible side effects

ο

ο

ο

ο

ο

ο

ο
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Extremely
important

of insulin medication, like allergic
reactions and reactions at the
injection site which may cause
redness, swelling and itching

DISPLAY Q22 IF CHECKED 2 AND 3 IN Q4
22. Assume you needed to use insulin to control your diabetes. When selecting an insulin product for managing
diabetes, how important is it to achieve each of the following treatment goals? Please rate the importance of
each using the scale below:
(ROTATE ITEMS)
Not at all
important

Very
important

Somewhat
important

Neither
important
nor
unimportant

Somewhat
important

Very
important

Fasting (morning before breakfast)
blood sugar (glucose) levels to goal
levels

ο

ο

ο

ο

ο

ο

ο

Making it easy to take insulin in a
public place (where people might
see you)

ο

ο

ο

ο

ο

ο

ο

Convenient for me to carry with me
during the day

ο

ο

ο

ο

ο

ο

ο

Post prandial (after meal) glucose
levels to goal levels

ο

ο

ο

ο

ο

ο

ο

Control blood sugar (glucose)
levels to goal levels

ο

ο

ο

ο

ο

ο

ο

Flexibility in time required between
insulin doses and eating

ο

ο

ο

ο

ο

ο

ο

Selecting the best product I can
afford

ο

ο

ο

ο

ο

ο

ο

Minimizing weight gain from
insulin therapy

ο

ο

ο

ο

ο

ο

ο

Minimizing the frequency of
monitoring blood sugar (glucose)
with finger-stick test

ο

ο

ο

ο

ο

ο

ο

Making it easy to accurately
measure the correct dose of insulin
dose

ο

ο

ο

ο

ο

ο

ο

Avoiding symptoms of low blood
sugar or hypoglycemia (such as
sweating, trembling, dizziness,
blurred vision and fast heart beat)

ο

ο

ο

ο

ο

ο

ο

Reducing the possible side effects
of insulin medication, like allergic
reactions and reactions at the
injection site which may cause
redness, swelling and itching

ο

ο

ο

ο

ο

ο

ο
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Extremely
important

(SHOW PRODUCT PROFILES)

23. Earlier you rated how important the treatment goals were. Now considering the product profiles you just
read, please rate each product in terms of how well it may meet the treatment goals listed in the table below
using a 7-point scale where: “1” = “Product performance is worst on this treatment goal” and “7” =
“Product performance is best on this treatment goal.”
If you are not sure how to rate a product on a treatment goal, please rate it as “0” to indicate that you do not
have sufficient information. If you need to re-read the profile please scroll up and come back to answer the
questions:
(ROTATE ITEMS)
Control blood sugar (glucose) levels to goal levels

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Avoiding symptoms of low blood sugar or hypoglycemia (such as sweating, trembling, dizziness,
blurred vision and fast heart beat)
1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Flexibility in time required between insulin doses and eating

1 – “Product
performance
is WORST
on this item”

2

3

4

Insulin

91

5

needle/syringe
Insulin Pen
Inhaled insulin

Selecting a product that I can afford

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Minimizing the frequency of monitoring blood sugar (glucose) with finger-stick test

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Reducing the possible side effects of insulin medication, like allergic reactions and reactions at the
injection site which may cause redness, swelling and itching

1 – “Product
performance
is WORST
on this item”

2

3

4

Insulin
needle/syringe
Insulin Pen
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5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Inhaled insulin

Keeping your blood sugar levels stable (avoiding high and low blood sugar levels)

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Making it easy to accurately measure the correct dose of insulin dose

1 – “Product
performance
is WORST
on this item”

2

3

4

5

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Fasting (before breakfast) blood sugar (glucose) levels to goal levels

1 – “Product
performance
is WORST
on this item”

2

3

4

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

93

5

Minimizing weight gain from insulin therapy

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Convenient for me to carry with me on a regular day

1 – “Product
performance
is WORST
on this item”

2

3

4

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Selecting the products with lower out-of-pocket cost

1 – “Product
performance
is WORST
on this item”

2

3

4

Insulin
needle/syringe
Insulin Pen
Inhaled insulin
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Post-prandial (after meal) glucose levels to goal levels

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Making it easy to take insulin in a public place (where people might see you)

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

Reducing the pain or discomfort of taking insulin

1 – “Product
performance
is WORST
on this item”

2

3

Insulin
needle/syringe
Insulin Pen
Inhaled insulin
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Selecting the best product I can afford

1 – “Product
performance
is WORST
on this item”

2

3

4

5

6

7 – “Product
performance
is BEST on
this item”

0 – “Do not
have
sufficient
information”

Insulin
needle/syringe
Insulin Pen
Inhaled insulin

24. Based on the information provided to you about 3 products, and if there was no difference in the cost of the
products, which one of the following would you prefer?
Insulin needle/syringe
Insulin pen
Inhaled insulin
No preference, will take whatever the doctor prescribes
25. Now consider the out-of-pocket monthly cost of taking insulin in the product information and your personal
insurance coverage, which one of the following would you prefer?
Insulin needle/syringe
Insulin pen
Inhaled insulin
No preference, will take whatever the doctor prescribes

26. Now assume that the next time you visit your doctor, your doctor asks you to start taking inhaled insulin to
better control your blood sugar levels. He writes you a prescription for inhaled insulin considering your
doctor’s recommendation and the information you just read for inhaled insulin, how likely would you be to
be fell the prescription and begin using inhaled insulin?
Very unlikely
ο

Unlikely

Undecided

ο

ο

Likely
ο

Very likely
ο

27. Assume that you read in a magazine or saw a promotional advertisement for inhaled insulin, if you needed
to take short acting insulin, how likely would you be to ask your doctor about using the inhaled insulin?
Very unlikely
ο

Unlikely

Undecided

ο

ο
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Likely
ο

Very likely
ο

28. In general, would you say your health is: (Check only one)
Excellent
Very good
Good
Fair
Poor

29. Which of the following best describes the highest grade or level of schooling you have completed or the
highest degree you have earned? Check only one
Some grade school
Some high school
High school diploma
Some college
Associate’s degree
Bachelors degree
Master’s degree
Doctoral degree
Do not wish to answer
Other (please specify)_________

30. What was your approximate total annual household income before taxes last year? Check only one.
Under $5,000
$5000 to $9,999
$10,000 to $14,999
$15,000 to $24,999
$25,000 to $34,999
$35,000 to $49,999
$50,000 to $74,999
$75,000 to $99,999
$100,000 and above
Do not wish to answer

31. Which of the following describes you?
I have never smoked (non-smoker)
I am a regular smoker
I am an occasional smoker
I used to smoke, but I do not smoke now (Ex-smoker)

32. Gender:
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Male
Female

33. Please fill in the following categories:
Age (in year): ______
Current Height (in feet, inches): ______
Current Weight (in lbs, pounds): ______

34. Ethnicity:
African-American/Black
American Indian/Alaska native
Asian/Asian Indian
Caucasian/white
Hispanic/Chicano/Latino
Native Hawaiian/ Pacific Islander
Other (please specify)_______

Thank you note (for disqualified respondents)
Thank you for your willingness to participate in our survey. The survey is only relevant for Type 2 diabetic patients
who are currently taking insulin or more than one oral anti-diabetic medication.

Thank you note (after completion)
This concludes your participation in the study. Thank you for your time!

Click Here to Exit
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APPENDIX B
PRODUCT PROFILES
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Please take a few minutes to go through the information carefully and then answer the questions that follow.
Insulin is a hormone that your body produces to help convert the food you eat into energy. For individuals that have
been diagnosed with diabetes (high blood sugar levels), the body doesn't make enough insulin, or it can't effectively
use the insulin it produces. In these cases, the doctor may prescribe insulin therapy. Insulin therapy includes
subcutaneous injections of insulin, which are often required to be taken multiples times a day. The required dose of
insulin depends on how your blood sugar levels are controlled and your doctors’ recommendation.
As you may already be aware, there are several ways in which you can take insulin like using syringes/needles to
take a shot of insulin from a vial and insulin pens. Currently, there is a new form of rapid-acting insulin that is
under development. This insulin does not need to be injected as the current insulin, rather it is inhaled. The
following information describes the different forms of rapid-acting insulin – vials/syringes, pens and inhaled. Please
read this information carefully and then answer the questions that follow.

INSULIN THERAPY USING NEEDLES/VIALS – tried and true
Insulin is available in a vial and the patient takes the required dose
using a syringe. A shot or injection is usually taken in the stomach,
thighs or hands. In recent years thinner and shorter needles have been
developed, making the injection less painful.
•

•
•

Dosage: Wash your hands before measuring and injecting insulin.
Insulin is measured in units marked on the side of the syringe.
This lets you measure the exact number of units that your doctor
has ordered for you. Before injecting each dose, clean the
injection site with rubbing alcohol.
Time of dosing: The rapid-acting insulin should be given within 5 to 15 minutes before or after a meal. Premeal
hypoglycemia may occur if the time between injection and eating is much greater than 15 minutes.
Storage: Insulin vials do not require refrigeration while in use but should be kept at room temperature [below
86°F (30°C)] away from direct heat and light. Insulin vials not in use should be
stored in a refrigerator, but not in the freezer.
• Side effects/Safety: The most common side effects of insulin therapies are low
blood sugar (hypoglycemia) and weight gain. Other possible side effects include
reactions at the injection site (like redness, swelling and itching).
• This type of insulin has been available for years and has been shown to be safe
in controlling or managing blood glucose levels.
• Costs: The average patient out of pocket monthly cost of taking insulin via vial
and syringe is approximately $15-$30 per month.
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INSULIN THERAPY USING INSULIN PENS - easy to carry, dose and use
Insulin pens are similar to a syringe in that they have a needle at the tip of the pen and the insulin is pre-loaded in the
pen. Therefore, it does not require the patient to draw the insulin when taking a shot. It also eliminates the need to
carry a vial.
•

•

•
•

•
•

There are two basic types: disposable and reusable. Disposable pens
come already filled with insulin, whereas re-usable pens have a
replaceable cartridge of insulin.
The pens make it easier for patients to measure correct insulin dose
which can be conveniently dialed up and often afford the elderly and
visually impaired a greater degree of independence
Pen offers less injection pain than a syringe
Dosage: no need to draw an insulin dose since the pen has the vial of
insulin built in. You simply turn a dial to the desired dose, insert the needle and press a plunger to inject the
insulin. You replace the needle before each injection.
• Time of dosing: The rapid-acting insulin should be given within 5 to
15 minute before or after a meal. Premeal hypoglycemia may occur
if the time between injection and eating is much greater than 15
minutes.
• Storage: They do not require refrigeration while in use but should be
kept at room temperature [below 86°F (30°C)] away from direct heat
and light. Pens not in use should be stored in a refrigerator, but not in
the freezer.
• Side effects/Safety: The most common side effects of insulin therapy
are low blood sugar (hypoglycemia) and weight gain. Other possible
side effects include reactions at the injection site (like redness,
swelling and itching).
This type of insulin has been available for years and has been showed to be safe in controlling or managing
blood glucose levels.
Costs: The average patient out of pocket cost of taking insulin via pen is approximately $15-$30 per month.
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INSULIN THERAPY USING INHALED INSULIN – designed to allow a more flexible lifestyle
•
•

•
•

•
•
•

•

The insulin is taken using a palm sized device.
This device allows rapid acting mealtime insulin to be
inhaled, which dissolves in the lung and then travels into
the bloodstream.
The device is light in weight, discreet and easy to use and
carry.
Dosage: Patients put insulin doses pre-packaged in
cartridges into the inhaler and turn the mouthpiece to
release the insulin.
Time of dosing: It should be given within 5 to 15 minutes
before or after a meal.
Storage: Should be kept at room temperature [below
86°F (30°C)]. Do not refrigerate or freeze.
Side effects/Safety: Compared to insulin taken as a shot via syringe or pen, inhaled insulin has a lower risk of
low blood sugar (hypoglycemia) and weight gain. When taken by the inhaled route, this insulin acts like the
insulin produced by the body and therefore the high and lows in sugar levels are less, even when individuals
inhale it and don’t eat. May need to be avoided in smokers and patients with unstable or poorly controlled lung
disease.
Costs: The average patient out of pocket cost of taking insulin via inhaled insulin is approximately $25-$45 per
month.
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